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Summary: Lafora disease (LD) is a fatal childhood epilepsy caused by recessive mutations in
either the EPM2A or EPM2B gene. A hallmark of LD is the intracellular accumulation of
insoluble polysaccharide deposits known as Lafora bodies (LBs) in the brain and other tissues. In
LD mouse models, genetic reduction of glycogen synthesis eliminates LB formation and rescues
the neurological phenotype. Therefore LBs have become a therapeutic target for ameliorating
LD. Herein, we demonstrate that human pancreatic α-amylase degrades LBs. We fused this
amylase to a cell-penetrating antibody fragment, and this antibody-enzyme fusion (VAL-0417)
degrades LBs in vitro and dramatically reduces LB loads in vivo in Epm2a-/- mice. Using
metabolomics and multivariate analysis we demonstrate that VAL-0417 treatment of Epm2a-/mice reverses the metabolic phenotype to a wild-type profile. VAL-0417 is a promising drug for
the treatment of LD and a putative precision therapy platform for intractable epilepsy.
Introduction
The progressive myoclonic epilepsies (PMEs) are a group of inherited disorders characterized by
recurrent seizures, myoclonus, and progressive neurological decline. There are currently no
treatments for PMEs, and anti-epilepsy drugs are palliative at best (Shahwan et al., 2005). Lafora
disease (LD; epilepsy, progressive myoclonus type 2, EPM2) is a severe form of PME that
typically manifests with tonic-clonic seizures and myoclonic jerks in the early teen years
followed by rapid neurological deterioration, increasingly severe and frequent epileptic episodes,
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dementia and death within ten years of onset (OMIM: 254780). LD is caused by mutations in the
EPM2A or EPM2B genes that encode laforin, a glycogen phosphatase, and malin, an E3
ubiquitin ligase that ubiquitinates enzymes involved in glycogen metabolism (reviewed in
(Gentry et al., 2018)). LD is distinguishable from other PMEs by the presence of cytosolic
polysaccharide inclusions known as Lafora bodies (LBs) most notably in the brain, where they
are found in neuronal cell bodies dendrites, and astrocytic processes, and in other tissues such as
muscle, heart, and liver. Among the PMEs, LD is uniquely considered a glycogen storage disease
(GSD). Independent studies from multiple groups demonstrated that Epm2a-/- and Epm2b-/mice, similar to LD patients, develop LBs and exhibit neurodegeneration, neurological
impairments, and increased susceptibility to seizures (Criado et al., 2012; DePaoli-Roach et al.,
2010; Duran et al., 2014; Ganesh et al., 2002; Garcia-Cabrero et al., 2012; Garcia-Cabrero et al.,
2014; Tiberia et al., 2012; Valles-Ortega et al., 2011).
Glycogen and starch are the major carbohydrate storage molecules in mammals and plants,
respectively (Brewer and Gentry, in press). Mammalian glycogen, LBs, and starch are all
glucose polymers (i.e. polysaccharides) composed of α-1,4-linked linear chains of glucose and α1,6 linked branch points, but they have different properties. Glycogen consists of linear chains of
~13 glucose units that each give rise to two branches, producing a highly water-soluble molecule
with a maximum diameter of 42 nm (Graham et al., 2010). LBs, which form in the absence of
functional laforin or malin, are comprised of abnormal polysaccharide referred to as
polyglucosan. The term polyglucosan refers to any glucose polymer that is abnormal, and other
types of polyglucosan bodies have been described in some GSDs (Cavanagh, 1999). Unlike
glycogen, LBs are water-insoluble, hyperphosphorylated, contain long glucose chains, and range
in size from a few microns to up to 35 or 40 μm (Nitschke et al., 2013; Sakai et al., 1970;
Tagliabracci et al., 2008; Yokoi et al., 1968). Dr. Gonzalo Rodriguez Lafora first described these
inclusions in patient autopsies, noting their histochemical similarity to plant starch (Lafora,
1911). Decades later Sakai and colleagues isolated these inclusions from patient tissue and
showed that LBs are indeed structurally more similar to starch than to glycogen (Sakai et al.,
1970; Yokoi et al., 1968). Plant starch is composed of infrequently branched, longer glucose
chains that exclude water and allow for much larger, more energy-dense molecules to form (up
to 100 μm in diameter) (Ball et al., 2011; Emanuelle et al., 2016; Tester et al., 2004). Plant starch
and LBs both contain significantly more covalently bound phosphate and longer glucan chains
than mammalian glycogen (DePaoli-Roach et al., 2015; Gentry et al., 2009; Sakai et al., 1970).
Loss of laforin or malin function results in the transformation of glycogen molecules into
hyperphosphorylated polyglucosan molecules with an altered chain length distribution, and these
aberrant molecules, prone to precipitation, accumulate to form LBs (Sullivan et al., 2017). How
laforin and malin prevent this process is still being defined.
Reactive astrocytes and activated microglia upregulated in aged Epm2a-/- and Epm2b-/mice, particularly in the hippocampus (Duran et al., 2014; López-González et al., 2017; SanchezElexpuru et al., 2017; Turnbull et al., 2011). These glial markers are used to measure
neurodegeneration in these models. Results from multiple labs have established that
accumulation of polyglucosan drives this gliosis in both LD and non-LD models. Glycogen
synthase is the only mammalian enzyme able to catalyze glucose polymerization in vivo. Epm2b/- mice lacking glycogen synthase (Gys1) in the brain are devoid of cerebral glycogen and LBs,
exhibit no gliosis, and have normal electrophysiology (Duran et al., 2014). A similar phenotypic
rescue was observed when Gys1-/- mice were crossed with Epm2a-/- mice (Pederson et al.,
2013). Furthermore, Epm2b-/- mice lacking just one Gys1 allele in the brain have reduced
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glycogen and also show near complete rescue of these phenotypes (Duran et al., 2014). Epm2a-/and Epm2b-/- mice lacking Protein Targeting to Glycogen (PTG), a protein that promotes
glycogen synthesis, also exhibit reduced LB accumulation, and neurodegeneration and
myoclonic epilepsy are resolved in these animals (Turnbull et al., 2011; Turnbull et al., 2014).
These results demonstrate that decreased or complete absence of the glycogen synthesis
machinery ablates LB formation and neurodegeneration in LD mouse models. The reverse has
also been observed: overexpression of a constitutively active form of glycogen synthase in
otherwise wild type animals drives neurodegeneration in both flies and mice (Duran et al., 2012).
The accumulating polysaccharide in transgenic animals overexpressing glycogen synthase is a
polyglucosan (i.e. abnormal) rather than normal glycogen (Raben et al., 2001). Collectively, the
aforementioned studies demonstrate that cerebral LB accumulation is pathogenic. These studies
have both elucidated the molecular etiology of LD and have made LBs an obvious therapeutic
target.
Efforts to develop a targeted therapy (i.e. precision medicine) for LD are ongoing (Brewer
and Gentry, 2018; Brewer et al., 2019). One form of precision medicine that has been utilized for
treating GSDs is the introduction of exogenous replacement enzymes. Enzyme replacement
therapy has proven effective for Pompe disease (OMIM: 232300), an inherited GSD (van der
Ploeg et al., 2010). Pompe patients are deficient in the lysosomal enzyme that degrades
glycogen, acid α-glucosidase (GAA), and are currently treated with a recombinant human form
of this protein known as rhGAA or alglucosidase alfa (Myozyme®, Lumizyme®, Genzyme)
(Kishnani et al., 2007; van der Ploeg et al., 2010). The uptake of rhGAA is a receptor-mediated
endocytic process that targets rhGAA to the lysosome. However, there is a significant portion of
cytosolic glycogen in Pompe patients, and since rhGAA only targets lysosomal glycogen, those
with large pools of cytoplasmic glycogen do not respond well to the current therapy (Thurberg et
al., 2006). In LD, LBs are entirely cytosolic. Histological studies from patient tissues report that
LBs are not membrane bound, and this observation has been confirmed in mouse models
(Berard-Badier et al., 1980; Criado et al., 2012; Ishihara et al., 1987; Van Hoof and HagemanBal, 1967). Thus, a therapeutic enzyme degrading LBs must be delivered to the cytosol.
Although cytosolic targets remain challenging for protein therapeutics, antibody-based
delivery platforms provide a means for penetrating the cell membrane (reviewed by (Rehman et
al., 2016)). The monoclonal anti-DNA autoantibody 3E10 and its antigen-binding (Fab) and
variable domain (Fv) fragments can be fused to an enzyme to facilitate cytosolic delivery in
multiple cell types (Hansen et al., 2006; Hansen et al., 2005; Weisbart et al., 1998). This
antibody-enzyme fusion (AEF) strategy has proven successful for the replacement of a cytosolic
enzyme and rescue of X-linked myotubular myopathy in mice (Lawlor et al., 2013). A Fab-GAA
fusion has similar efficacy to reduce glycogen in Pompe mice with the additional advantage of
targeting both lysosomal and cytosolic glycogen and is now in Phase 1/2 clinical trials (Valerion
Therapeutics, 2016; Yi et al., 2017). Rather than utilizing the AEF platform to deliver a
replacement enzyme, we generated an AEF designed to penetrate cells and degrade pathogenic
LBs. We show that an AEF comprised of the humanized 3E10 Fab fragment and pancreatic αamylase degrades LBs in vitro, degrades glycogen and polyglucosan in situ, and reduces LB load
in vivo. Furthermore, we utilize a metabolomics approach to demonstrate that the drug reverses
the physiological effects of LB accumulation.
Results
3

Construction of an antibody-enzyme fusion (AEF) that degrades starch
An important consideration in designing an LB-degrading enzyme is that LBs are less sensitive
to enzymatic hydrolysis than normal glycogen. Resistance to digestion with diastase (a generic
term for enzymes that degrade polysaccharides) is a defining feature of LBs and one factor that
differentiates LBs from glycogen (Girard et al., 2013; Van Hoof and Hageman-Bal, 1967).
However, in routine histological preparations, embedded sections are only incubated with
diastase for 15-30 minutes prior to staining. Early studies reported that LBs in tissue sections can
be digested by a 5-10 hour incubation with pancreatic α-amylase and γ-amylase (i.e.
amyloglucosidase), but they are somewhat resistant to digestion by β-amylase or glycogen
phosphorylase (Nikaido et al., 1971; Sakai et al., 1970; Yokoi et al., 1968).
Another consideration in the AEF design is the biochemical structure of the target LBs
themselves. Glycogen, starch, and LBs are all polysaccharides with different properties. LBs are
considered more similar to starch than glycogen due to their insolubility, elevated phosphate
levels, and the increased chain length of their constituent glucose chains. We hypothesized that
starch could serve as a proxy for LBs in a screen to identify a candidate therapeutic enzyme. We
screened a panel of amylases to determine which possessed robust activity against starch, and
therefore would likely degrade LBs. We found that only α-amylases showed significant activity,
and pancreatic α-amylase had the highest capacity to degrade starch (Fig. 1A). Pancreatic αamylase is naturally secreted by the human pancreas for digestion of carbohydrates in the gut,
cleaving α-1,4 linkages to yield maltose, maltotriose and low molecular weight oligosaccharides.
It has previously been shown to digest LBs in tissue sections (Nikaido et al., 1971). Thus,
pancreatic α-amylase is a putative candidate for degrading LBs.
An AEF designated as VAL-0417 was generated by fusing the humanized 3E10 IgG1 Fab
heavy chain fragment with human pancreatic α-amylase and then coexpressed in HEK293-6E
cells with the corresponding light chain as a secreted heterodimer (Fig. 1B). The fusion was
purified from HEK293-6E cell conditioned media by affinity chromatography, and the purity
was determined by reducing and nonreducing SDS-PAGE (Fig. 1C). The addition of βmercaptoethanol (BME) dissociated the heavy and light chains, producing two distinct bands of
75 and 25 kDa. In the absence of BME, only a single band was observed at 100 kDa,
corresponding to the intact Fab-amylase fusion. The specific activity of an α-amylase was then
tested using a substrate that consists of seven glucose moieties and a chromophoric paranitrophenyl moiety that is capped with an ethylidine group to block the action of other hydrolytic
enzymes (Fig. 1D) (Kruse-Jarres et al., 1989). Using this substrate, the specific activity of VAL0417 was determined to be 10.5 units/mg.
VAL-0417 activity was then tested against plant starch. After a 2-hour incubation, VAL0417 degraded starch in a dose-dependent manner: 5 μg of enzyme released 61 μg of soluble
glucan product (Fig. 1E). We employed scanning electron microscopy (SEM) to visualize the
effects of degradation on the starch granules. In the absence of enzymes, starch granules had a
smooth, polyhedral or subspherical appearance (Fig. 1F). Overnight treatment with VAL-0417
produced cavities in the granule surface, representing areas of active hydrolysis, and numerous
partially degraded granules were visible (Fig. 1F). When the ratio of VAL-4017 to starch was
reduced by 10-fold, amylolysis was less extensive: fewer partially degraded particles were
visible and most granules were only decorated with small pits (Fig. S1). Other groups have
observed similar "pitting" of starch granules with α-amylase and other amylolytic enzymes (Jung
et al., 2017; Sujka, 2007).
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Isolation and characterization of LBs from LD mice
Polysaccharides (both glycogen and LBs) are typically purified from Epm2a-/- and Epm2b-/mice based on a method described by Pflüger in 1909 where the tissue is heated in strong KOH
and the glycogen is precipitated with alcohol (Good, 1933; Pflüger, 1909). The isolated particles
are 15-65 nm in size when visualized by transmission electron microscopy (Tagliabracci et al.,
2008), orders of magnitude smaller than the intact LBs observed in fixed tissue sections, and the
method does not separate LBs from glycogen. It is well-established that heating changes the
physiochemical properties of starch, leads to granule swelling, and enhances its sensitivity to
enzymatic degradation (Kulp, 1981). Therefore, it is likely that this protocol disrupts the native
structure of LBs, intermixing the individual polyglucosan constituents of LBs with normal
glycogen molecules. We developed a procedure for isolating pure and native LBs from tissue so
that we could test the sensitivity of LBs to VAL-0417 degradation.
A study from the 1960s showed that native LBs could be isolated from patient brain tissue by
centrifugation steps and successive treatments with proteolytic enzymes (Yokoi et al., 1968). We
designed a similar method for isolating native LBs from the brain, heart and skeletal muscle of
Epm2a-/- mice (Fig. 2A, see STAR Methods). Our procedure separates soluble glycogen
(present in the supernatant) from the insoluble LBs (Fig. S2, see STAR Methods). Final LB
yields from each tissue type corresponded to ~30% of the total polysaccharide detected in the
original tissue homogenate (Fig. 2B and C). Phosphate content of the final LBs from skeletal
muscle was 5-fold higher than phosphate in normal muscle glycogen, which is in agreement with
published results (Fig. 2D) (Tagliabracci et al., 2008). Iodine spectral scans of the purified LBs
were compared to those of commercial glycogen and amylopectin, the major component of plant
starch to which LBs are most similar. While glycogen has a peak maximum at ~440 nm when
stained with Lugol's iodine, amylopectin has a right-shifted spectrum and a peak maximum at
560 nm due to its reduced branching (Fig. 2E) (Krisman, 1962). The spectra of the purified LBs
were also shifted toward longer wavelengths, with peak maxima at 510-520 nm (Fig. 2E). These
data indicate that the purified LBs are less branched than glycogen, consistent with previous
reports on Epm2a-/- and Epm2b-/- mice (Tagliabracci et al., 2008; Valles-Ortega et al., 2011).
Final LB preparations were also stained with Lugol's iodine and examined by light
microscopy. Minimal tissue debris was observed and the LBs tended to clump (Fig. 2, F to H).
LBs from different tissues also had noticeably distinct morphologies. Brain LBs were generally
spherical, sub-spherical or irregularly shaped (Fig. 2F), and a range of sizes were observed: the
maximum diameter of a single LB ranged from 1-10 μm, most being 2-4 μm (Fig. S3A). These
preparations also had a significant amount of granular material that stained less intensely with
iodine; small amounts of this material were visible throughout the slide but appeared to form a
large aggregate in some fields of view (Fig. S3D). Similar PAS-positive granular material has
been reported in fixed tissue sections from patient brain biopsies or LD mice, which are referred
to as dust-like particles, or simply "dust" (Edgar, 1963; Machado-Salas et al., 2012; Van Heycop
Ten Ham, 1975; Van Hoof and Hageman-Bal, 1967).
Heart LBs were more often ellipsoid or ovoid in shape, frequently with pointed ends,
although some were sub-spherical like the brain LBs (Fig. 2G). Heart LBs also ranged in
diameter/length from 1-10 μm, most of them being 2-4 μm (Fig. S3B). Dust-like particles were
also observed among the heart LBs, although no masses of granular material were observed as
with the brain LBs (Fig. S3E). LBs have been reported in LD patient cardiac tissue: in fixed and
stained tissue sections, they are irregularly shaped or elongated with pointed ends (Edgar, 1963;
Van Heycop ten Ham and Jager, 1963; Yokota et al., 1987; Yokota et al., 1988). Although these
5

reports do not discuss dust-like particles in the heart, they appear to be present in the
micrographs, particularly in the studies that involve immunostaining with an LB-specific
antibody (Yokota et al., 1987; Yokota et al., 1988). PAS-stained cardiac sections from malin KO
mice show LBs of similar shape and size and diastase-resistant granular material (Criado et al.,
2012; DePaoli-Roach et al., 2010). LBs from skeletal muscle were the smallest and most
homogenous in size and shape: the vast majority were ellipsoid and 1-3 μm long (Fig. 2H and
S3C). There appeared to be virtually no dust in these preparations. In LD patients, LBs have
been reported to similarly range in diameter from 0.2-2 μm in skeletal muscle (Van Heycop Ten
Ham, 1975).
We also utilized SEM to visualize the purified LBs. We found that washing LBs in ethanol
and allowing them to dry in a vacuum concentrator, the method used for visualization of starch
granules, caused the LBs to aggregate and form very large clumps after being applied to carbon
tape (Fig. S4). It was difficult to distinguish individual LBs within the clumps against the
similarly textured carbon tape. As an alternative drying method, LBs were diluted in water,
applied to a mounted silicon wafer and lyophilized prior to visualization. This method yielded
less aggregated LBs and allowed for their morphological analysis. These micrographs showed
that LBs from all three tissues had a similarly textured appearance (Fig. 3), in contrast to the
smooth surface of starch (Fig. 1F). As observed via light microscopy, individual brain LBs up to
10 μm in diameter were observed, which were spherical or irregularly shaped (Fig. 3A). Ovoid
and ellipsoid LBs from heart and small ellipsoid LBs from skeletal muscle were also consistent
with our light micrographic observations (Fig. 3B and C). Visualization of skeletal muscle LBs
at very high magnification (30,000×) revealed the fine texture of the LBs (Fig. 3D).
Degradation of LBs by VAL-0417
As described above, native LBs purified from different tissues possess unique morphology. To
determine if VAL-0417 could degrade the different types of LBs, we incubated 50 μg of Epm2a/- LBs from brain, heart and skeletal muscle with VAL-0417. We observed a consistent doseresponse effect: 1 μg VAL-0417 released 6-9 μg of glucan (i.e. an oligosaccharide composed of
several glucose moieties) into the soluble fraction, indicating 12-18% of the LBs had been
degraded (Fig. 4A). Increasing the dose to 10 μg of VAL-0417 released over twice as much, 1519 μg of glucan, corresponding to 30-38% of the total substrate. A small amount of soluble
glucan (5 μg or less) was observed in the samples lacking enzyme, so we visualized the soluble
fractions from each treatment by light microscopy. We observed some LB fragments in the
soluble fraction that did not sediment with centrifugation for LBs with and without VAL-0417
(Fig. S5). We consistently observed that mechanical agitation caused some LBs to fragment.
However, agitation was required to keep the LBs in suspension.
We also purified LBs from skeletal muscle of 12-month-old Epm2b-/- mice and found they
were indistinguishable from Epm2a-/- skeletal muscle LBs in appearance, size and iodine spectra
(Fig. S6). We observed a comparable dose-response effect of VAL-0417 on Epm2b-/- LBs: 1 μg
and 10 μg VAL-0417 released 16% and 32% of the total, respectively (Fig. 4A). In a similar
experiment, we incubated LBs with 10 μg VAL-0417 overnight and then visualized the product
by staining the insoluble fraction with Lugol's iodine. Untreated LBs had no change in
appearance and appeared largely intact after the overnight agitation, but VAL-0417 treatment led
to fewer iodine-positive LBs and the appearance of a filamentous degradation product (Fig. 4B).
Previous work has shown that various proteins are associated with LBs in vivo (Criado et al.,
2012; Machado-Salas et al., 2012). Our purification protocol removes these proteins, so it is
6

possible that an intact protein coat could inhibit LB degradation by VAL-0417. To test this
possibility, we measured LB load in crude muscle homogenates after incubation with VAL-0417
using iodine absorbance. While virtually no absorbance was detected at 550nm in the WT
samples with or without VAL-0417 treatment, treatment of the Epm2a-/- samples with VAL0417 reduced iodine absorbance by >50%, indicating substantial LB degradation (Fig. 4C).
Since VAL-0417 is a potential therapeutic, it is important to define the soluble product(s) it
releases from LBs. Pancreatic α-amylase is reported to release glucose, maltose, maltotriose and
other short oligosaccharides (Robyt and French, 1967). Amylolytic products can be separated
and quantified via high-performance anion-exchange chromatography coupled with pulsed
amperometric detection (HPAEC-PAD). We digested LBs from Epm2a-/- skeletal muscle with
VAL-0417 for a total of 168 hours with additional enzyme added every 24 hours. At 24-, 48- and
72- hour time points, the soluble fractions of LB digestions were removed for HPAEC-PAD
analysis. At all 4 time points, maltose and glucose were the major degradation products,
followed by small amounts of oligosaccharides with 3, 4, 5 and 6 degrees of polymerization (DP3, 4, etc., where each DP corresponds to one glucose unit) (Fig. 4D and Fig. S7). Quantitation of
the glucose and maltose peaks showed that maltose levels remained constant throughout
degradation and glucose levels increased steadily over the 168-hour experiment (Fig. 4E).
Cumulatively, these data demonstrate that VAL-0417 robustly digests brain, heart and muscle
LBs in vitro. It is not inhibited by endogenous proteins in muscle homogenates, and its
degradation products are primarily glucose and maltose, with a few short oligosaccharides.
VAL-0417 uptake and polysaccharide degradation in situ
To degrade LBs in vivo, VAL-0417 must penetrate and remain active inside cells. Cell
penetration of the parent 3E10 mAb and its fragments require functional expression of the
membrane equilibrative nucleoside transporter 2 (ENT2), which is involved in a nucleoside
salvage pathway and is ubiquitously expressed in rodents and humans (Crawford et al., 1998;
Hansen et al., 2007; Lu et al., 2004). VAL-0417 uptake and activity were assessed in two cell
lines: fibroblast-derived Rat1 cells accumulating normal glycogen and HEK293 cells engineered
to accumulate polyglucosan (HEK293-PTG/PP1Cα) (Fig. S8; see STAR Methods). After a 20hour treatment with increasing doses of VAL-0417, cells were washed, lysed, and probed for
ENT2 and VAL-0417. ENT2 protein levels were stable in both lines, though Rat1 cells have
slightly higher levels, and were unchanged with increasing concentrations of VAL-0417 (Fig.
5A). Western blot analysis of VAL-0417 using an antibody for AMY2A revealed a dosedependent increase in protein levels (Fig. 5A). Total polysaccharide levels per well (glycogen in
Rat1 cells and polyglucosan in HEK293-PTG/PP1Cα cells) were also measured. Both Rat1 and
HEK293-PTG/PP1Cα lines displayed a dose-dependent decrease in total polysaccharide after
treatment with VAL-0417 (Fig. 5B), with reductions of 30% and 26% of the untreated control,
respectively. Thus, VAL-0417 is both taken up by cells and degrades glycogen and polyglucosan
in situ.
In vivo uptake of VAL-0417 and LB reduction in Epm2a-/- mice
We have shown that VAL-0417 degrades LBs in vitro, penetrates cultured cells, and degrades
glycogen and polyglucosan in situ. We next tested VAL-0417 uptake in an in vivo setting and
biodistribution after peripheral injections. We performed intramuscular (IM) injections of VAL0417 to determine if it can be detected in the injected muscle and other tissues and if it is quickly
degraded and/or cleared. We injected 0.6 mg VAL-0417 into the left gastrocnemius muscles of
7

WT C57BL/6 mice, then 2 and 24 hours post-injection, euthanized the mice and collected right
and left gastrocnemii, right and left quadriceps, heart, liver, and brain. The same tissues were
also collected 2 hours post-injection from control mice treated with phosphate-buffered saline
(PBS). We designed a sandwich enzyme-linked immunosorbent assay (ELISA) to specifically
detect VAL-0417 in tissue homogenates with very low background. At the 2-hour VAL-0417
post-injection time point, 3200 ng of VAL-0417 per mg protein (15% of the injected amount)
was detected in the injected (left) gastrocnemius (Fig. 6A). After 24 hours, VAL-0417 levels
dropped by 20-fold (to 151 ng per mg protein), 0.7% of the initial injected amount. At 2 hours,
low levels of VAL-0417 (2-9 ng per mg protein, 0.02-0.1% of the injected amount) were
detected in the other muscles, heart, liver, and brain, indicating some VAL-0417 had entered
circulation. After 24 hours, VAL-0417 levels nearly returned to baseline in muscles, liver, and
brain, but remained constant in the heart. Since blood circulates the entire body of a mouse
within minutes, the very high levels of VAL-0417 in the injected muscle 2 and 24 hours postinjection strongly suggest that VAL-0417 is taken up by cells rather than immediately cleared.
The low levels of VAL-0417 in non-injected tissues indicate VAL-0417 entered the circulation.
In mice, ENT2 expression levels are high in brain, muscle and heart, and low in liver (Lu et al.,
2004). It is possible that these tissues took up a small amount of VAL-0417 from the circulation
that was mostly cleared by 24 hours. ENT2 levels were probably not limiting since VAL-0417
levels were similar regardless of tissue differences in ENT2 expression. It is notable that VAL0417 levels remained constant in heart even after 24 hours.
We next tested whether IM injections of VAL-0417 reduced polysaccharide levels in vivo in
Epm2a-/- mice. To determine polysaccharide levels in individual muscles, we utilized the
Pflüger method rather than our native LB protocol because the Pflüger method recovers ~100%
of the polysaccharides, enables more accurate and sensitive measurements from small amounts
of tissue, and yields both normal glycogen and LBs. 10-month-old WT and Epm2a-/- mice were
injected in the right gastrocnemius with either 0.6 mg VAL-0417 or PBS. Three injections were
performed over the course of one week, on days 1, 4, and 7. On day 8 the mice were euthanized,
and the injected muscles were collected for total polysaccharide quantification. Polysaccharide
levels in the WT mice were similar regardless of treatment, and consistent with reported skeletal
muscle glycogen levels for C57BL/6 mice (Tagliabracci et al., 2008). In Epm2a-/- animals,
VAL-0417 treatment reduced polysaccharide levels by 53% relative to the PBS-treated controls
(Fig. 6B). These data indicate that in vivo, VAL-0417 does not decrease normal glycogen levels,
but degrades LBs in Epm2a-/- mice.
Intravenous (IV) injections are sometimes preferable to IM injections to achieve rapid and
extensive bioavailability of the drug to various tissues, but the preferred route depends on the
drug (Jin et al., 2015). We tested whether a high dose of VAL-0417 administered intravenously
could reduce LBs in the heart. Like skeletal muscle and brain, heart tissue has a very high LB
load, and cardiac abnormalities have been reported in both LD mice and in patients (de Graaf et
al., 1989; Oksel et al., 1999; Villalba-Orero et al., 2017). Furthermore, our biodistribution
experiment indicated there was less turnover of VAL-0417 in the heart compared to other tissues
(Fig. 6A). 8-month-old WT and Epm2a-/- animals were injected via the tail vein with either PBS
or VAL-0417 over the course of two weeks, on days 1, 5, 8 and 13. The mice were euthanized on
day 14, and hearts were removed and flushed with PBS. A small section of tissue was excised for
fixation and periodic acid-Schiff (PAS) staining, and the remaining tissue was flash frozen and
analyzed for polysaccharide content via the Pflüger method. The glycogen content of the heart in
WT animals is very low in comparison to skeletal muscle (Pederson et al., 2004). Accordingly,
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we found that polysaccharide levels in WT animals were very low levels irrespective of
treatment (Fig. 6C). In contrast, polysaccharide levels in the PBS-treated Epm2a-/- mice were
very high in comparison to the WT animals and were reduced by 67% after the two-week
treatment regimen with VAL-0417 (Fig. 6C).
Results from the fixed, PAS-stained heart sections were consistent with polysaccharide
quantification. PAS-positive deposits, i.e. LBs, were not observed in WT tissue irrespective of
treatment and were abundant in tissue of PBS-treated Epm2a-/- mice (Fig. 6D and 6E).
Conversely, Epm2a-/- mice treated with VAL-0417 showed a marked reduction in LBs (Fig. 6E).
These data collectively indicate that after IM or IV injection, VAL-0417 penetrates cells,
remains active, and degrades LBs in vivo.
Cerebral LB accumulation drives epilepsy and neurodegeneration in LD (Duran et al., 2014).
Most drugs, particularly antibody-based drugs, do not cross the blood-brain barrier (Kumar et al.,
2018). Any therapy targeting cerebral LBs must be delivered into the CNS. There are multiple
routes of drug administration to the CNS that bypass the blood-brain barrier. The intrathecal (IT)
route involves injection of the drug directly into the spinal cord or the subarachnoid space. Drugs
can also be injected directly into the ventricles of the brain via intracerebroventricular (ICV)
injection. Both IT and ICV are considered safe and well-tolerated drug delivery routes in both
pediatric and adult populations, but the procedures have different risks and benefits (CohenPfeffer et al., 2017; Kumar et al., 2018; Vuillemenot et al., 2016).
We first tested IT versus ICV administration of either PBS or VAL-0417 in WT mice over a
period of 3 days. The IT catheter was surgically implanted intrathecally at the lumbar region.
The ICV cannula was implanted in the cerebral lateral ventricle. The IT catheter and ICV
cannula were each attached to an osmotic pump that delivered a continuous infusion of VAL0417 (0.08 mg/day) or PBS for 3 days. Mice were sacrificed on the fourth day and brains were
removed and sectioned as shown (Fig. 7A). Homogenates from each section were analyzed via a
VAL-0417 ELISA assay (Fig. S9A) and amylase assays were used to quantify VAL-0417
activity (Fig. S9B). Negligible ELISA signal was detected in tissue treated with PBS either by IT
or ICV, and amylase activity in the tissue was very low. In tissues treated with VAL-0417, VAL0417 levels were markedly higher with ICV administration compared to IT. In most slices,
amylase activity was also markedly higher with ICV treatment of VAL-0417. After ICV
administration, VAL-0417 levels and activity were nearly equal in all slices, indicating this route
facilitates homogenous distribution of the drug throughout the brain. In contrast, IT
administration only resulted in high VAL-0417 levels in the most caudal sections, which are
nearest the brain stem. Since LBs are abundant throughout the cortex and cerebellum, a thorough
distribution is necessary and thus ICV administration is preferable to IT. Furthermore, these data
are indicative of cellular uptake of VAL-0417 in the brain, since the drug was not cleared in the
period after infusion (day 3) and before euthanasia (day 4). These data also demonstrate that the
drug remains active after uptake.
To target cerebral LBs, we administered VAL-0417 directly into the cerebral lateral ventricle
of 5-month-old Epm2a-/- mice. A continuous infusion of VAL-0417 (0.08 mg/day) or PBS was
administered for 28 days via the ICV cannula and pump. Mice were then euthanized, and brains
were removed and sectioned as shown (Fig. 7A). Polysaccharides were isolated from each
section, quantified, and normalized to protein levels. Polysaccharide levels relative to protein
content were lowest in the rostral section and highest in the caudal section (Fig. 7B). This is the
first- time polysaccharide distribution across different brain regions has been quantitated in
Epm2a-/- mice, and is consistent with the high levels of LBs observed in histological sections
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from brainstem and cerebellum (Criado et al., 2012; Rubio-Villena et al., 2018; Valles-Ortega et
al., 2011). Treatment with VAL-0417 reduced the polysaccharide load in all sections, with
statistical significance in the two most caudal sections that contain the highest glucan load (Fig.
7B).
To define initial pre-clinical parameters regarding optimal treatment length, we performed a
second ICV experiment to determine whether a shorter treatment regimen still reduced the
amount of polysaccharide in the brain. 7-month old Epm2a-/- mice received a continuous
infusion of VAL-0417 at an equivalent rate (0.08mg/day) or PBS for 7 days. On the 8th day, the
mice were euthanized, and the brains were hemisected along the medial longitudinal fissure. The
left hemisphere was frozen and pulverized for biochemical analyses, and the right hemisphere
was fixed and sectioned for PAS staining. The brains of age-matched untreated cohorts of WT
and Epm2a-/- animals were similarly analyzed as surgical controls. Polysaccharide levels relative
to tissue weight in untreated and PBS-treated animals were consistent with what has been
previously reported for Epm2a-/- animals of this age, i.e. 2-3 times higher than WT levels (<2
μmol glucose/g tissue) (Nitschke et al., 2017; Tagliabracci et al., 2008). Treatment with VAL0417 reduced brain polysaccharide in the Epm2a-/- mice by 69% compared to untreated and
PBS-treated Epm2a-/- mice (Fig. 7C). The amount of VAL-0417 in the treated brains was 249
ng per mg protein (Fig. 7D). This value is slightly higher than the VAL-0417 levels in the
injected gastrocnemius 24 hours after IM injections in WT mice (Fig. 6A). Fixed and PASstained tissue slices showed an abundance of LBs in the PBS-treated Epm2a-/- brains similar to
age-matched untreated Epm2a-/- controls with no observable LBs in age-matched WT animals
(Fig. 7E and Fig. S10). In the untreated and PBS-treated Epma2-/- animals, LBs were least
abundant in the frontal cortex, more abundant in the thalamus, and most abundant in the
cerebellum and brainstem (Fig. S10). This regional distribution is very consistent with the slicespecific quantification we performed via the Pflüger method (Fig. 7B). Strikingly, the VAL-0417
treated Epm2a-/- brains are virtually devoid of LBs in all regions (Fig. 7E, S10). .
Metabolomic profiles as a biomarker for VAL-0417 treatment
It is critical to establish that the reduction of LBs in the brain produces a physiological
amelioration of LD pathology. However, like many mouse models of human diseases, LD
models do not completely recapitulate the human phenotype (Perlman, 2016). In contrast to
patients, LD mice do not have a reduced lifespan, neurophysiological impairments are difficult to
detect in young mice, and in older mice, they are often significant only by a small margin
(Ganesh et al., 2002; Garcia-Cabrero et al., 2012; Garcia-Cabrero et al., 2014; Sanchez-Elexpuru
et al., 2017). Furthermore, although older mice develop myoloclonic jerks, they do not have
spontaneous grand mal seizures (Ganesh et al., 2002; Turnbull et al., 2011; Valles-Ortega et al.,
2011). Seizure susceptibility must be detected in older mice using kindling agents such as
pentylenetetrazol or kainate (Duran et al., 2014; Garcia-Cabrero et al., 2014; Valles-Ortega et al.,
2011). The discrepancy between human and mouse phenotypes is a particularly common issue
that arises when studying neurological diseases. The extreme differences between the size,
lifespan, and complexity of the two species are just a few of the potential causes of this problem
(Dawson et al., 2018).
Conversely, metabolic pathways are more highly conserved between rodents and humans,
especially disease models. The metabolic signatures of Alzheimer’s disease mouse models
parallel those of patients and are therefore readily translatable (Trushina and Mielke, 2014).
Metabolomic similarities between humans and mice have also been observed in Huntington’s
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disease, type 2 diabetes, nonalcoholic fatty liver disease, and colorectal tumors (Barr et al., 2010;
Manna et al., 2014; Salek et al., 2007; Underwood et al., 2006). It is likely that the metabolic
changes that underlie a disease are similar in the two species, although they may have speciesspecific physiological manifestations.
Glycogen is formed from UDP-glucose, and its catabolism leads to the release of glucose-1phosphate, which is rapidly converted to glucose-6-phosphate (Brown and Ransom, 2007).
Glucose-6-phosphate is a central molecule in cellular metabolism, supplying carbon for
glycolysis, the pentose phosphate pathway, and amino acid synthesis. Therefore, altered brain
glycogen metabolism is expected to produce measurable shifts in the cerebral metabolome. We
sought to measure these changes in the cerebral metabolome to define the physiological outcome
of VAL-0417 treatment. We utilized gas chromatography-mass spectrometry (GCMS) to assess
central carbon metabolites of glycolysis and the TCA cycle, as well as amino acids, nucleotides,
and mono-, di- and trisaccharides (Fiehn, 2016; Fiehn et al., 2000; Kind et al., 2009). Polar
metabolites were extracted from the pulverized brain tissue of the same mice that were treated
with PBS or VAL-0417 via ICV for 8 days. Age-matched untreated WT and Epm2a-/- animals
were used as controls. We identified over 100 metabolites from all four treatment groups to
utilize in a multivariate analysis, which included both principle component analysis (PCA) and
heat map clustering. The metabolites analyzed and relative abundance of each are listed in Table
S1. The 2-dimensional PCA plot using all available metabolomic data revealed three discrete
clusters (Fig. 7F). Metabolites of untreated WT and Epm2a-/- groups segregated into two
discrete groups, while metabolites of the PBS-treated Emp2a-/- mice comprised a third group.
The metabolic differences between the untreated and PBS-treated animals are likely due to the
physiological effects of surgery and ventricular infusion. Strikingly, metabolites of the VAL0417 treated Epm2a-/- mice clustered tightly within the WT group, indicating that after LB
degradation by VAL-0417 the cerebral metabolism returned to normal. We further corroborated
this result with clustering heatmap analysis (Fig. S11). While the metabolic profiles of the
untreated Epm2a-/- animals were distinct, metabolites of the VAL-0417 treated Epm2a-/animals were interspersed with the WT animals.
We previously demonstrated that VAL-0417 degrades LBs in vitro by releasing glucose,
maltose and short oligosaccharides (Fig. 4D and 4E). To determine whether oligosaccharides
were accumulated in the brain tissue, the relative spectral abundance of mono-, di- and trisaccharides was determined. There was a significant increase in each oligosaccharide in the brain
tissue from the VAL-0417 treated Epm2a-/- animals compared to the other groups (Fig. 7G).
These results coupled with the overlapping metabolic profile of the VAL-0417 treated animals
with the untreated WT animals demonstrate the effectiveness of VAL-0417 and metabolic
profiling as a means to assess treatment efficacy.
Discussion
LD is caused by mutations in one of two genes both encoding enzymes that impact glycogen
architecture. Efforts from multiple labs have shown that LBs are the pathogenic epicenter of LD,
and LB removal has become a therapeutic approach for the treatment of LD (Brewer and Gentry,
2018; Brewer et al., 2019). In this study, we combine insights from the fields of antibody-based
therapeutics, GSDs, carbohydrate metabolism, and LD to design an AEF that degrades LBs in
vitro, penetrates cells and reduces polysaccharide levels in situ, and decreases polysaccharide
load in vivo via both IM and ICV injection. This is the first time a significant LB reduction has
been achieved in adult LD mice by the use of a drug and the first report of overall brain
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metabolism in LD mice. Importantly, we define the use of metabolomics for monitoring drug
efficacy in LD mouse models.
Antibody-based drugs have made a major impact on the treatment of cancer, autoimmune
and inflammatory diseases with worldwide revenues of ~$89 billion in 2016 (Carter and Lazar,
2018). Antibody-based drugs are typically whole IgGs designed to bind and block receptors,
deplete target cells, downregulate a receptor or initiate signaling. Bispecific antibodies, antibody
fragments and antibody-drug conjugates (ADCs) are also being developed across multiple
diseases, further expanding the diversity of therapeutics utilizing antibody targeting (Baeuerle
and Reinhardt, 2009; Beck et al., 2017; Carter and Lazar, 2018; Moolten and Cooperband, 1970).
In this report, we report a novel class of antibody-based drugs with a similar construction to
ADCs: antibody-enzyme fusions (AEFs). Rather than delivering a cytotoxin, AEFs deliver an
enzyme to a specific target. The antibody or antibody fragment is essential both for targeting and
cellular penetration. AEFs have recently been reported for the treatment of multiple congenital
disorders, including a muscle wasting disorder known as X-linked myotubular myopathy and the
GSD Pompe disease. For X-linked myotubular myopathy, the deficient lipid phosphatase
myotubularin fused to an Fv fragment was delivered by intramuscular injection and improved
muscle function in a mouse model of myotubular myopathy (Lawlor et al., 2013). For Pompe
disease, a Fab fragment fused to GAA delivered intravenously reduced glycogen load and
alleviated pathology in GAA-deficient mice (Yi et al., 2017). These two studies illustrate that
enzyme replacement therapy, which can be problematic for cytosolic enzymes, can be enhanced
by fusion of the replacement enzyme with a cell-penetrating antibody fragment. We now
demonstrate that VAL-0417, an AEF comprised of a Fab fragment fused to pancreatic αamylase, degrades LBs and reduces polysaccharide loads in vivo. Unlike the two studies above,
VAL-0417 does not replace a missing enzyme, but rather delivers a natural human enzyme to a
new target. Since LBs are structurally similar to plant starch, and α-amylase naturally degrades
dietary starch in the human digestive tract, α-amylase is a logical choice for the VAL-0417
payload.
It is important to distinguish normal glycogen from polyglucosan. Polyglucosan bodies
(PGBs) have been defined as "small, non-membrane-bound cytoplasmic structures composed
largely of unusual glucose polymers" (Raben et al., 2001). They are typically a pathological
feature of GSDs, although PGBs known as corpora amylacea are a hallmark of normal aging and
neurodegenerative disorders (Augé et al., 2018; Cavanagh, 1999). PGBs are not found in all
GSDs, and not all PGBs are identical with respect to physiochemical structure. The polyglucosan
found in Cori's disease is characterized by short outer chains, while the polyglucosan of LD,
Anderson disease, Adult Polyglucosan Body Disease, and Tarui disease contain very long chains
(Illingworth and Cori, 1952; Raben et al., 2001). The Pflüger method, originally designed to
purify normal glycogen, also precipitates polyglucosan. In this report, we refer to Pflügerisolated material as polysaccharide, since it contains both glycogen and polyglucosan.
Furthermore, the Pflüger method includes an alkaline boiling step that solubilizes polyglucosan
and destroys LB superstructure. LBs (and PGBs) may be considered a higher-order structure of
polyglucosan. The LB purification protocol we designed does not include the alkaline boil.
Rather, it separates native LBs from normal, soluble glycogen.
LBs from the different tissues displayed varied morphologies. Brain LBs were the most
irregular in size and shape, included dust-like particles, and reached the largest size. LBs from
brain exhibited the greatest variation in size, which is consistent with clinical observations: LBs
from patient brain micrographs are 3-40 μm and LB dust-like granules are even smaller
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(Minassian, 2001; Van Heycop Ten Ham, 1975). A recent microscopic study of Epm2b-/- mice
showed that astrocytic LBs are on average smaller than neuronal LBs, more irregularly shaped,
and clustered, while neuronal LBs are larger, more spherical, and isolated (Augé et al., 2018).
LBs in the heart were also surprisingly large and included some dust-like particles. LBs from
skeletal muscle appeared well organized: they were very small and homogenous in shape, and no
dust-like particles were present. It is not clear why such variation in LB size and shape exists in
the brain and heart, in contrast to the homogeneity found in skeletal muscle. One possibility is
that LB size is limited by the dimensions of the cell or subcellular region it occupies. For
example, in patients, dogs, and mice, LBs can be found in the cell bodies of Purkinje neurons,
which can be up to 40 μm in diameter (Jian et al., 1990; Machado-Salas et al., 2012; Van Heycop
Ten Ham, 1975). In astrocytes, LBs are typically found in processes, which can be very long but
are only a few microns wide (Augé et al., 2018; Rubio-Villena et al., 2018). However, cell size
constraints do not explain the difference between heart and skeletal muscle LBs, since cardiac
and skeletal myocytes are similar in size. It is well known that glycogen metabolism is
remarkably different in astrocytes, neurons, cardiomyocytes and skeletal myocytes. Skeletal
myocytes may sequester LBs more efficiently than cardiomyocytes, consolidating them into
smaller, discrete units. In brain and heart, the dust-like particles may represent a pre-aggregated
form of polyglucosan, while the larger particles may represent polyglucosan aggregates that have
been sequestered and compacted by the cell. Active cellular sequestration of polyglucosan has
been proposed to explain the large, dense, and spherical LBs observed in some neurons
(Machado-Salas et al., 2012).
Although LBs from all three tissues had iodine spectral peak maxima at similar wavelengths,
indicative of similar degrees of branching, the higher amplitude of the spectra of brain and heart
LBs suggests that they may contain longer chains compared to LBs from skeletal muscle
(Krisman, 1962; Swanson, 1948). Indeed, Nitschke et al. showed using HPAEC-PAD that in
Epm2a-/- and Epm2b-/- mice, brain glycogen had a more exacerbated shift in chain length
distribution than muscle glycogen (Nitschke et al., 2017). Although the brain is most severely
affected in LD and a neurological phenotype predominates, heart failure and arrhythmia have
been reported in LD patients, and Epm2a-/- and Epm2b-/- mice have metabolic cardiomyopathy
(de Graaf et al., 1989; Oksel et al., 1999; Villalba-Orero et al., 2017). Glycogen metabolism is
variable with tissue type: glycogen synthase and glycogen phosphorylase have tissue-specific
isoforms that are disparately regulated by cellular signals (Roach, 2002); the ultrastructure of
glycogen is different under different metabolic conditions and in different organs (Ryu et al.,
2009; Sullivan et al., 2014); subcellular glycogen pools are variable (Graham et al., 2010); and
both phosphate levels and average chain length differ with species and tissue type (Illingworth et
al., 1952; Lomako et al., 1993). Due to these differences, the LBs may be more pathological in
brain and heart than in skeletal muscle. Conversely, different cell types may be more sensitive to
the presence of the LBs, and/or the metabolic perturbations induced by the LBs may have
distinct consequences in different organs. Tissue-specific differences are important to consider
throughout the clinical development of VAL-0417. ICV administration of VAL-0417 may
attenuate neurological symptoms, but cardiac, liver and/or muscular pathology may require
treatment by intravenous or intramuscular injection of VAL-0417.
We found that VAL-0417 primarily releases maltose and glucose from LBs, and glucose
levels gradually increased over time, as expected for an α-amylase. Cytosolic free glucose would
likely be phosphorylated to produce glucose-6-phosphate, entering central carbon metabolism.
Although maltose is not considered a typical participant in intracellular energy utilization,
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studies have shown that maltose can be transported into and out of cells and metabolized in cell
culture and humans after intravenous infusion (Leong et al., 2017; Young and Weser, 1971). The
small oligosaccharides (DP-3, DP-4, etc.) would likely remain cytosolic and inert until they are
further metabolized to glucose and maltose. Our metabolomics approach revealed a significant
increase in mono-, di- and trisaaccharides in the VAL-0417 treated brains. These in vivo data
strongly support our in vitro oligosaccharide profiling of VAL-0417 degradation products.
Strikingly, the metabolomic profile of Epm2a-/- mice treated with VAL-0417 is
indistinguishable from the WT mouse metabolic profile. These data strongly suggest that the
oligosaccharide products are not detrimental and may be metabolically inert.
Importantly, IM and IV injections of VAL-0417 in Epm2a-/- mice reduced the
polysaccharide load (i.e. LBs and glycogen) to WT levels but did not decrease glycogen levels in
WT skeletal muscle or heart, respectively. Glycogen levels in WT heart tissue is already very
low, and the levels remained negligible after IV treatment with VAL-0417. In contrast, we
observed that VAL-0417 reduced polysaccharide levels in cell culture. It should be noted that the
cell culture studies were performed in high glucose media, known to promote glycogen
accumulation and the cells are engineered to increase glycogen levels. Thus, it is possible that a
reduction in polysaccharides with VAL-0417 treatment is only detected when polysaccharide
levels accumulate above a baseline level, as glycogen accumulates in cultured cells or LB in LD
tissues. When glycogen levels drop below a certain threshold due to degradation by VAL-0417,
the cellular machinery may respond to restore those levels. Glycogen is likely to be maintained at
a certain baseline level in vivo in muscle, and this may explain why no change was observed in
WT muscle treated with VAL-0417. The observation that VAL-0417 reduced polysaccharide
levels in Epm2a-/- muscle, heart and brain indicates LBs are degraded in vivo.
Although both IT and ICV injections are performed in the clinic, delivery to the CNS
remains a significant challenge (Calias et al., 2014; Wolak and Thorne, 2013). Drug distribution
is highly dependent on fluid movement in the CNS, which is a relatively nascent field of research
(Abbott et al., 2018; Kumar et al., 2018; Plog and Nedergaard, 2018). While the field has defined
fluid movement, detailed biodistribution of actual drugs via ICV and IT delivery is ongoing
(Kumar et al., 2018). In this study, we demonstrate that a 150 kDa AEF is modestly distributed
throughout the brain after IT administration and maximally distributed by after ICV
administration (Fig. S9). Similarly, ICV administration of anti-amyloid antibodies for the
treatment of Alzheimer’s disease resulted in widespread distribution throughout the murine brain
(Chauhan and Siegel, 2004). Our data support a recent study demonstrating that the
bioavailability of antibodies to the brain after IT injection is size-dependent (Pizzo et al., 2018).
Our results indicate that VAL-0417 can cross cellular barriers between the ventricles and brain
parenchyma (e.g. ependyma, perivascular lining cells, and/or pia and glia limitans), they also
highlight the differences in drug permeability and diffusion between the ICV and IT routes.
Importantly, we utilized a metabolomics approach to quantify the physiological effects of
VAL-0417 treatment. Using principal component analysis, we found that the profile of polar
brain metabolites from WT and Epm2a-/- mice cluster into discreet groups. Treatment of Epm2a/- mice with the VAL-0417 shifted the Epm2a-/- profile to mimic the WT cluster, reflecting a
restoration of normal metabolism. These results illustrate a positive physiological response and
amelioration of metabolic derangement in LD animals after VAL-0417 treatment. Studies in
multiple disease contexts have shown that the metabolic changes in humans and mice are highly
correlated (Barr et al., 2010; Manna et al., 2014; Salek et al., 2007; Trushina and Mielke, 2014;
Underwood et al., 2006). Furthermore, metabolomics is now being employed to identify
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biomarkers in human biofluids or tissues for monitoring disease progression and therapy efficacy
(Johnson et al., 2016; Spratlin et al., 2009). A particularly relevant example is the use of the
tetrasaccharide glucose (Glc4) as a biomarker for Pompe disease (Bobillo Lobato et al., 2016).
Elevated levels of Glc4 have also been observed in patients with GSD Ia and III, and urinary
excretion of the Glc4 in Pompe patients correlates with response to Myozyme treatment (An et
al., 2005; Manwaring et al., 2012). The dramatic upregulation of oligosaccharides in VAL-0417
treated mouse brain tissue suggests these molecules could be utilized as biomarkers for VAL0417 therapy in humans.
We have demonstrated that VAL-0417 is a putative precision therapy for LD, an intractable
epilepsy. Currently, >30% of epilepsies, including LD, are resistant to available antiseizure drugs
(ASDs) and are known as refractory epilepsies (Loscher and Schmidt, 2011). More than 35
different iterations of ASDs have been discovered over the past 150 years with most of them
acting primarily on ion channels or neurotransmitters. Due to this focus on one mode of action,
the high proportion of refractory epilepsies has remained constant since the 1850s (Loscher and
Schmidt, 2011; Scharfman, 2015). The underlying causes of these refractory epilepsies must be
identified in order to develop more effective therapies. As the molecular basis of LD has been
defined, we have now developed an AEF that targets its underlying cause. As molecular
etiologies in other epilepsies become clear, precision therapies, possibly also utilizing the AEF
platform, become feasible. LD is also a non-classical GSD. There are over 14 different types of
GSDs characterized by glucan accumulations, and 1 in 20,000 people have some form of GSD
though the individual types are considered rare (Adeva-Andany et al., 2016; Ozen, 2007). While
the glycogen in some GSDs is of normal structure like in Pompe disease, other GSDs such as
Cori disease and Andersen disease are characterized by polyglucosans, like LD (Adeva-Andany
et al., 2016). Two AEF drugs (VAL-0417 and Fab-GAA) have now been shown to target
cytosolic polyglucosan (the present study) and normal glycogen in both the cytosol and
lysosome, respectively (Yi et al., 2017). These drugs could be repurposed and/or modified to
target glycogen in other GSDs. Not only is VAL-0417 the first drug with the potential for
providing a significant clinical benefit to LD patients, it is an example of a precision therapy and
expands the repertoire of antibody-based drugs that can be used to treat human disease.
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Limitations of Study
This study employs LD mouse models and the use of metabolomics to determine the
physiological benefit of LB degradation by VAL-0417. Metabolomics is an extremely powerful
technique routinely used for biomarker discovery, and it is increasing utilized to provide insights
into disease onset, progression and response to therapy (Johnson et al., 2016). Although the
metabolic changes in humans and mice are often strongly correlated (Barr et al., 2010; Manna et
al., 2014; Salek et al., 2007; Trushina and Mielke, 2014; Underwood et al., 2006), our analysis
provides only a general overview of the physiological and metabolic state of the brain. It is not
possible to determine the relative contributions of cellular populations (e.g. neurons and glia) or
specific pathway aberrations (e.g. oxidative stress and proteostasis) to the metabolic profiles.
Finally, like all mouse models of neurological diseases, LD mice do not perfectly phenocopy the
human disease. Further pre-clinical studies will be conducted to validate the physiological
benefit of VAL-0417 administration and LB degradation for the treatment of LD.
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STAR�Methods
CONTACT FOR REAGENT AND RESOURCE SHARING
Researchers may obtain VAL-0417 with a material transfer agreement from Valerion
Therapeutics. All reasonable requests for collaboration involving materials used in the research
will be fulfilled provided that a written agreement is executed in advance between Valerion
Therapeutics and the requester (and his or her affiliated institution). Further information and
requests for reagents may be directed to, and will be fulfilled by the corresponding author
Matthew S. Gentry (matthew.gentry@uky.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Epm2a-/- (DePaoli-Roach et al., 2012; Ganesh et al., 2002) and Epm2b-/- (DePaoli-Roach et al.,
2010) mice have been previously described. C56Bl/6 WT, Epm2a-/- and Epm2b-/- animals were
maintained in a 12:12 hr light-dark cycle and were given ad libitum access to food and water.
Both male and female mice were used since there are no sex differences associated with LD
(Gentry et al., 2018). All procedures were approved by the UK Institutional Animal Care and
Use Committee (IACUC) as specified by the 1985 revision of the Animal Welfare Act.
METHOD DETAILS
Expression and purification of VAL-0417
VAL-0417 was designed and produced by Valerion Therapeutics (Concord, MA). The cDNA
encoding the human IgG1 Fab-linker-AMY2A heavy chain and light chain were synthetically
produced with codon optimization for mammalian cell expression and cloned into pTT5.
HEK293 cells expressing a truncated variant of the Epstein Barr Virus nuclear antigen 1
(HEK293-6E) increase the volumetric yield of monoclonal antibodies and fragments and were
used for VAL-0417 expression (Jager et al., 2013). 2 1L cultures of HEK293-6E cells in 2L
shake flasks were transfected with 1 mg of total plasmid DNA/L (1:1 ratio heavy chain:light
chain) culture using PolyPlus linear Q-PEI at a 1:1.5 (w/v) DNA:PEI ratio. Culture parameters
were monitored using a ViCell XR (Beckman Coulter) for density and viability. Culture was
harvested 5 days post transfection via centrifugation for 5 minutes at 1000×g. The conditioned
culture supernatant was clarified by centrifugation for 30 minutes at 9300×g.
Pre-packed CaptureSelect IgG-CH1 affinity columns (Fisher) were equilibrated in PBS (pH
7.2). VAL-0417 from 2 L of exhausted supernatant was top-loaded onto affinity columns (2 x 1
mL columns in tandem) at 4°C overnight. The column was washed with approximately 15
column volumes (CV) of PBS, 15 CV of buffer B (1×PBS with 500 mM NaCl, pH 7.2) and 15
CV of PBS. The resin-bound fusion protein was eluted with 10 CV of Buffer C (30 mM NaOAc,
pH 3.5-3.6), collecting the protein in 1 mL fractions diluted in 1/10th volume Buffer D (3 M
NaAcetate pH~9.0) to neutralize. To minimize the elution volume, elution was paused for
several minutes between each fraction collected. Fractions were analyzed by A280 prior to
pooling fractions and pools were analyzed by SDS-PAGE. VAL-0417 remained in the nonbound pool from the first affinity chromatography pass. The above procedure was repeated to
capture remaining fusion protein. The affinity pools were combined prior to dialysis. The
combined CaptureSelect IgG-CH1 affinity pool (18 mL) was dialyzed against 3 x 1 L of dialysis
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buffer (20 mM Histidine, 150 mM NaCl, pH 6.5) at 4°C. The dialyzed pool was concentrated to
1 mg/mL using a VivaSpin 20 (10K MWCO, PES membrane) centrifugal device prior to final
analysis and storage at -80°C. Purified Fab-AMY was analyzed by size exclusion
chromatography (Agilent HP1100) showing a single peak before and after a freeze-thaw cycle,
indicative of a single, stable species. Activity of the purified protein was quantified by an
amylase activity colorimetric kit (BioVision) utilizing the amylase-specific E-G7-pNP substrate
(Kruse-Jarres et al., 1989).
Iodine-based measurements
Lugol's iodine was prepared as a 20×stock (1.5 M KI and 100 mM I2). To detect LBs in
preliminary purifications, 50 μL samples from purification fractions were boiled for 15 minutes
on a 95°C heat block, clarified by centrifugation (16,000×g for 1 min), and 35 μL of the
supernatant was added to 50 μL 1×Lugol's iodine and 15 μL water for 100 μL total (Fig. S2A).
To analyze iodine absorbance of polysaccharide from LB purifications, Pflüger-isolated
polyglucosan fractions were added to 50 μL 1×Lugol's iodine for 100 μL total and absorbance
was measured at 550 nm. Absorbance was graphed alongside glucose-based concentrations to
illustrate the fractionation of polyglucosan and glycogen into supernatant and pellet fractions,
respectively (Fig. S2B). For spectral scans, 50 μg LBs, rabbit liver glycogen (Sigma), and potato
amylopectin (Sigma) were solubilized by boiling for 30 min and added to 50 μL 1×Lugol's
iodine for 100 μL total. Absorbance scans were performed at 400-800 nm in 10 nm steps.
Purification of native LBs
19-24 month old Epm2a-/- mice were euthanized by CO2 and decapitation, and brain, heart and
hindlimb skeletal muscle were immediately harvested, flash frozen and stored at -80°C. 12
month old Epm2b-/- mice were euthanized by cervical dislocation, and muscle tissues were
similarly collected and stored. Tissues were pulverized over liquid N2 using a Freezer/Mill
Cryogenic Grinder (SPEX SamplePrep). Powdered tissue was weighed and homogenized on ice
in 4 vol. lysis buffer (100 mM Tris-HCl pH 8.0, 200 mM NaCl, 1mM CaCl2, 0.5% sodium azide)
using a Dounce tissue grinder. For larger volumes, the grinding pestle was attached to a
motorized drill. The homogenate was centrifuged for 10 min at 10,000×g at 4°C in a Ti-70 rotor
and Optima XPN-90 ultracentrifuge (Beckman Coulter) and the supernatant was removed. The
pellet was resuspended in an equivalent volume of lysis buffer, and 20% SDS was added for a
final concentration of 0.2%, and 20 mg/ml Proteinase K was added for a final concentration of
0.4 mg/ml. Proteolytic digestion was performed in a 37°C water bath overnight. The digested
samples were then syringe-filtered through 140 μm and 60 μm nylon net filters installed in
Swinnex filter holders (Millipore), centrifuged at 16,000×g for 5 min, and the supernatant was
removed. The LBs were resuspended in 10% SDS and then washed 5 times in LB buffer (10 mM
HEPES-KOH pH 8.0, 0.1% sodium azide) each time with centrifugation at 16,000×g for 5 min.
Final LB pellets were gently and thoroughly dispersed in LB buffer with a pipet. Polysaccharide
yield at various steps of the purification were determined using the Pflüger method (see below).
2 μL of LB preparations were stained with 5 μL 20× Lugol's iodine, mounted on glass slides with
a glass coverslip, and visualized at 100x using a Zeiss Axioimager Z1 equipped with an
AxioCam 1Cc5 color camera. Purified LBs were stored at -20°C.
Pflüger method for polysaccharide isolation
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Glycogen and polyglucosan from Epm2a-/- and Epm2b-/- mice have been purified and
characterized by multiple groups using the Pflüger method, but a chaotropic salt must be added
to enhance the efficiency of polyglucosan precipitation (Tagliabracci et al., 2008). We wanted to
clarify that under native conditions, and prior to the Pflüger treatment, LBs in Epm2a-/- and
Epm2b-/- tissues are intact, micron-sized structures (Fig. 2 F to H, Fig. 3, and Fig. S5B). Pflüger
treatment converts the LBs to much smaller polysaccharide molecules that are on the same
nanometer scale as glycogen molecules, but they contain elevated phosphate and an altered chain
length distribution (Nitschke et al., 2013; Tagliabracci et al., 2008). Thus, the term "LB" refers to
the native, micron-sized polysaccharide-containing structures found in LD tissues, and
"polyglucosan" refers to the abnormal polysaccharide comprising LBs, which is released with
Pflüger treatment.
The Pflüger method is direct and very sensitive and was used to track polysaccharide yield
throughout the native LB purifications or to detect polysaccharide content of mouse tissues for in
vivo studies. Aliquots from native LB purifications or tissue homogenates were added to 10 vol.
30% KOH, boiled for 2 hours, and allowed to cool. 2 vol. cold ethanol and 10 μL LiCl (1 M or
20 mM) were added, and samples were precipitated overnight at -20°C. Precipitated samples
were centrifuged for 10 min at 16,000×g at 4°C, the supernatant was removed, and the
polysaccharide pellet was resuspended in water. Two additional precipitations with cold ethanol
and LiCl were carried out, each for 1-2 hours at -20°C. The final pellet was washed in cold
ethanol and resuspended with vortexing in 200 μL water. Polysaccharide was quantified by
overnight hydrolysis with amyloglucosidase from Aspergillus niger (Sigma) and glucose
determination was carried out using the D-glucose kit (Fisher). Fluorescence (ex340/em445)
rather than absorbance of the NADPH product (stoichiometric to glucose) was measured for
higher sensitivity.
Separation of glycogen and LBs in LB purification
After the initial centrifugation step in the LB purification, a fraction of the heart and muscle
glycogen was consistently present in the supernatant (Fig. 2, B and C). In our preliminary
purifications, we found that the homogenate and pellet fractions stained brown with Lugol's
iodine after boiling, as did the final LBs and amylopectin, but the supernatants stained yellow
like glycogen (Fig. S2A). We also stained the Pflüger-purified polysaccharide fractions from our
large-scale preparations in Figure 2C with Lugol's iodine, measured absorbance at 550 nm, and
compared the values to the polysaccharide concentrations determined by hydrolysis and glucose
measurement (Fig. S2B). While the polysaccharide from the supernatant did not absorb at 550
nm, polysaccharide from the pellet, filtrate and final fractions produced a high absorbance
relative to concentration. Polysaccharide in the homogenate fraction was less absorbent relative
to concentration. These data indicate that the polysaccharide in the heart and muscle tissue
homogenates included both glycogen and polyglucosan (in the form of LBs), that were separated
into supernatant and pellet fractions after low-speed centrifugation. No polysaccharide was
detected in the supernatant fractions from brain (Fig. 2, B and C). This result is consistent with
the observation that in normal mice, glycogen levels are lower in brain than in other tissues in
part due to its rapid catabolism after euthanasia (Oe et al., 2016).
Determination of LB phosphate content
Muscle glycogen and LBs contain covalent phosphate linked to the C2, C3, and C6 hydroxyls of
glucose moieties, and the relative ratios of these modifications are equivalent (DePaoli-Roach et
22

al., 2015; Nitschke et al., 2013; Tagliabracci et al., 2011). Boiling in mild HCl hydrolyzes
glycosidic bonds and releases the acid-labile C2- and C3-linked phosphate leaving C6
phosphoesters intact in the form of glucose-6-phosphate (Nitschke et al., 2013). Thus, inorganic
phosphate after mild acid hydrolysis represents only C2- and C3-linked phosphate, i.e. two-thirds
of total phosphate. To determine phosphate content, skeletal muscle LBs were boiled for 2 hours
at 95°C in 1 M HCl. Reactions were neutralized with NaOH and inorganic phosphate in the
sample was determined using the Pi ColorLock Gold Phosphate Detection System (Innova
Biosciences). Glycogen purified from rabbit skeletal muscle as previously described was used as
a positive control, and the levels of phosphate detected using our method are consistent with twothirds of published total phosphate levels (DePaoli-Roach et al., 2015).
In vitro degradation assays
Corn starch and LB degradation experiments were performed in degradation buffer (30 mM
HEPES-KOH pH 7.5, 5 mM MgCl2, 5 mM CaCl2) and a total volume of 100 μL. Reactions were
performed in triplicate using PCR strip tubes and moderate agitation on a vortex to keep
substrates in suspension, and we found that this level of agitation did not affect enzyme activity.
Degradation reactions were allowed to proceed overnight (13-18 hours) unless otherwise
indicated, after which tubes were centrifuged to pellet undigested substrate. 50 μL of the
supernatant (containing the soluble degradation product) was transferred to a new tube with 50
μL 2 M HCl and boiled for 2 hours at 95°C in a C1000 thermocycler (Bio-Rad) to hydrolyze all
glucans to glucose. Samples were neutralized with 50 μL 2 M NaOH, and glucose was
determined using the D-glucose kit. For visualization of LB degradation product, degradation
reactions were allowed to proceed as above, and the reactions were centrifuged to pellet
undigested substrate. After 75 μL of the supernatant was removed, the remaining 25 μL was
resuspended, and 5 μL was stained with 5 μL 20× Lugol's iodine, mounted on glass slides with a
glass coverslip, and visualized using a Nikon Eclipse E600 using DIC/Nomarski contrast and an
AxioCam MRm camera at 100x. In addition to the D-glucose kit, the absorbance-based PGO
assay (Sigma) was also used to quantify glucose in starch degradation assays.
In vitro degradation of LBs in muscle homogenates was performed as follows: 300 mg of
skeletal muscle from WT or laforin KO mice was pulverized over liquid N2 and homogenized in
4 vol. degradation buffer. Homogenate was split into 2 × 500 μL aliquots, and 25 μg VAL-0417
was spiked into one aliquot for a final concentration of 0.05 mg/ml. Samples were incubated on a
rotator overnight at room temperature and the next morning centrifuged for 5 min at 16,000×g.
The supernatant was removed, and the pelleted material containing LBs was resuspended in
degradation buffer and boiled for 30 min on a 95°C heat block to solubilize LBs. The boiled
samples were clarified by centrifugation (16,000×g for 5 min) and 25 μL of supernatant was
added to a microplate. 50 μL of 1×Lugol's iodine and 25 μL of water were added to samples, and
absorbance was measured at 550 nm.
Scanning electron microscopy
Starch granules were incubated with enzymes in degradation buffer overnight while agitating,
washed in 1mL 100% ethanol, dried in a vacuum centrifuge, and applied to carbon tape on a pin
mount. Samples were coated with gold and platinum to improve sample conductivity, and
visualized under high vacuum at 2 kV using an FEI Quanta 250 field emission scanning electron
microscope. Washing in ethanol, drying, and manual application to carbon tape did not yield
satisfactory results for LB visualization (Fig. S4), so alternatively, diluted LBs were applied to a
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mounted silicon wafer, lyophilized, coated in gold and platinum, and visualized at 2 kV with the
FEI Quanta 250.
Profiling of degradation product by HPAEC-PAD
80 μg of LBs were treated with 2.67 μg of VAL-0417 in degradation buffer to a final
concentration of LBs at 1 μg/μL. The enzymatic reactions were done at 37°C in triplicates. 20 μL
samples were removed at 24, 48, 72 hour intervals followed by addition of 2.67 μg of VAL0417. The aliquots were stored at -20°C until they were run. The final reactions were continued
at 37°C for total of 168 hours. All samples were profiled using CarboPac PA-100 column
(Thermo-Dionex, 4 x 250 mm) and detected with PAD detector. 5 μL of samples from each time
point (corresponding to 5 μg LBs total) were injected on the column. Blank LBs and degradation
buffer were injected as controls. Glucose and maltose in the degradation reactions were
quantified by comparing with standards of known amount (Fig. S7A). 5 μg Maltrin100 was also
included as a standard for oligosaccharide profiling (Fig. S7E).
Cell culture studies of VAL-0417 uptake
Protein Phosphatase 1 (PP1) stimulates glycogen synthesis by both dephosphorylating and
activating glycogen synthase and inhibiting glycogen phosphorylase, the primary enzymes
catalyzing glycogen synthesis and degradation, respectively (Newgard et al., 2000). Protein
targeting to glycogen (PTG) is a regulatory, glycogen-targeting subunit of PP1 that stimulates
glycogen synthesis when overexpressed in cell lines (Printen et al., 1997; Worby et al., 2008).
Constitutive overexpression of PTG in WT mice has been shown to lead to cerebral
polyglucosan accumulation in Epm2b-/- mice (Duran et al., 2014). We sought to design a cell
line that accumulates polyglucosan like that which makes up LBs.
HEK293 cells (Graham et al., 1977) were co-transfected with plasmids pCDH-FLAG-PTG
and pCDH-(HA)3-PP1Cα-GFP harboring mouse PTG and the human PP1Cα (catalytic alphasubunit of PP1) cDNAs, respectively. Mixed clones were selected for ~10 days in the presence
of 1 μg/ml hygromycin and 0.2 mg/ml puromycin, expanded and stored in liquid N2. Analyses of
protein expression and glycogen synthase activity ratio in the absence and presence of glucose-6phosphate indicated that both proteins were expressed, and the glycogen synthase activity ratio
was increased 3-fold, from 0.02 in control cells to 0.06 in transfected cells. Quantitation of the
expression of PTG and PP1Cα is difficult because the basal levels are very low, undetectable
under our conditions.
For quantitation of polysaccharide levels HEK293, HEK293-PTG/PP1Cα and
Rat1fibroblasts (Skurat et al., 2000) were plated in 96-well plates at a density of 40,000
cells/well. After 48 hr, media was changed and the next day, the cells were washed 3 times with
PBS followed by overnight incubation at 40°C in 50 μL of 0.2 M sodium acetate pH 4.8
containing 0.2% Triton and 0.3 mg/ml amyloglucosidase (Aspergillus niger; Sigma). Identical
cell cultures were lysed in 50 μL of in 0.2 M sodium acetate pH 4.8 containing 0.2% Triton for
protein determination by the Bradford procedure.
After overnight digestion, polysaccharide was measured by transferring 40 μL samples to a
new 96-well plate. A 160 μL reaction mixture consisting of 0.375 M ethanolamine pH7.6, 5 mM
MgCl2, 1.12 mM NADP, 2.5 mM ATP and 0.2 Units of G6PDH (Roche Biochemicals
10127655001) was added and OD340 nm was recorded. Subsequently, 0.75 units of hexokinase
(Roche 11426362001) were added, the reaction incubated at room temperature for 30 min and
OD340 recorded again. Background absorbance was subtracted from sample absorbance and
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glucose equivalents were determined based a digested glycogen standard curve. The engineered
HEK293 line accumulated >30-fold more polysaccharide than the native HEK293 cells, and
twice the level of normal glycogen found in Rat1 cells (Fig. S6).
To determine the effect of VAL-0417 on polysaccharide degradation, cells were plated in 96well plates at a density of 40,000 cells/well, and after 4 days various concentrations of VAL0417 were added for 20 hr to fresh growth media. Cells were then washed 3 times with PBS,
fixed for 7 min with 3.7% formaldehyde in 90% ethanol, washed again 3 times with PBS and
polysaccharide content was determined by hydrolysis and glucose determination. Statistical
significance was assessed by using an unpaired Student t-test.
For Western analyses, 20 μg of total cell lysates were separated on SDS-PAGE and protein
transferred to nitrocellulose membranes that were probed with antibodies against human
pancreatic α-amylase (AMY2A) and ENT2 followed by appropriate HRP-conjugated secondary
antibodies and chemiluminescence.
Enzyme-linked immunosorbent assay
The capture antibody raised against the 3E10 Fab fragment was generated by Valerion
Therapeutics (Concord, MA). Wells of a 96-well plate were incubated with 100 μL of capture
antibody overnight (~16 hours) at a final concentration of 2 μg/ml in PBS. All incubations were
done in a humidified chamber. Wells were then rinsed 3 times with 200 μL PBS followed by
incubation for 1 hour with 200 μL of blocking solution (5% non-fat milk in PBS). Wells were
then rinsed 3 times with 200 μL PBS. 100 μL of diluted tissue homogenates were added and
incubated for 1 hour. Wells were then rinsed 3 times with 200 μL of Tris-buffered saline (TBS)
and 100 μL of primary antibody (anti-AMY2A) in 5% non-fat milk and TBS was added and
incubated for 1 hour. The wells were then washed (solution added and incubated for 5 minutes
before being removed) 3 times with TBS. 100 μL of secondary antibody (anti-rabbit IgG, HRPlinked) in 5% non-fat milk in TBS was added and incubated for 1 hour. Wells were then washed
5 times with TBS. 100 μL of TMB substrate was added and a timer started. After the highest
concentration of standard curve saturated or a pre-set time was met, the reaction was stopped by
adding 100 μL of stopping solution (0.18% H2SO4). The plate was then read for absorbance at
450 nm.
In vivo mouse studies
For each IM injection, 20 μL VAL-0417 (30 mg/ml; 0.6 mg per injection) or 20 μL PBS was
injected into one gastrocnemius. For the IV injections, mice were pretreated intraperitoneally
with diphenhydramine (15mg/kg) before each injection to prevent anaphylaxis. After the
diphenhydramine, the mice where kept under a heat lamp for twenty minutes. A Mouse Tail
Illuminator (BrainTree Scientific, Inc.) was used to restrain the mouse and an insulin
syringe/needle was used to inject PBS or VAL-0417 into the dorsal tail vein. 100 μL of PBS was
injected into IV control mice on days 1, 5, 8, and 13. For the IV treatment group, 100 μL of 30
mg/ml VAL-0417 (3 mg total) was administered on days 1 and 5, 100 μL of 20 mg/ml VAL0417 (2 mg total) on day 8, and 130 uL of 23 mg/ml VAL- 0417 (3 mg total) on day 13. At the
indicated time points post-injection(s), mice were euthanized by cervical dislocation and
decapitation. Tissues were harvested, flash frozen, powdered over liquid N2 using Freezer/Mill
Cryogenic Grinder (SPEX SamplePrep), and stored at -80°C. Powdered tissues were weighed,
homogenized in assay buffer from the BioVision amylase assay kit and protein concentration
was determined using the Pierce BCA Protein Assay Kit. For the ELISA assay, tissue
25

homogenates were diluted in PBS for a final concentration of 0.1 μg protein/μL in 100 μL.
Diluted homogenates were added to 96-well plates for the ELISA utilizing a capture antibody
binding the 3E10 Fab fragment and anti-AMY2A as the detection antibody. Polysaccharide
content was determined using the Pflüger method.
IT and ICV studies were performed by Northern Biomedical Research, Inc. (Spring Lake,
MI). Animals were anesthetized with a mixture of oxygen 0.5 to 1 L/min and isoflurane 1 to 5%
prior to and during the catheter implantation procedure. The IT catheter attached to an osmotic
pump was inserted at the cisterna magna and advanced caudally 2.5 cm to the lumbar region. The
ICV cannula attached to an osmotic pump was inserted into the cerebral lateral ventricle and
anchored VAL-0417 (30 mg/ml) or PBS was continuously administered via the IT catheter or
ICV cannula for 3, 8 or 28 days (0.11 μL/hr). On the day following the last day of infusion, mice
were euthanized by isofluorane/oxygen sedation and perfusion via the left cardiac ventricle with
0.001% sodium nitrite in heparinized saline. For the 3- and 28- day experiments, brains were
harvested, weighed, sectioned using a Rodent Brain Matrix (RBM-2000C, ASI Instruments) with
2.0 mm coronal section slice intervals, flash frozen and stored at -80°C. Slices were directly
homogenized in BioVision assay buffer using polypropylene pellet pestles in microcentrifuge
tubes. VAL-0417 levels and amylase activity were determined by ELISA and the BioVision
assay and normalized to protein content. Protein and polysaccharide content were determined by
BCA assay and the Pflüger method, respectively.
For the 8-day ICV experiment, brains were weighed, separated into two hemispheres
(longitudinal dissection) and each hemisphere was weighed. The right hemisphere was rinsed in
PBS and submerged in 10% neutral buffered formalin (NBF) for approximately 48 hours at room
temperature with periodic agitation. After approximately 48 hours, the 10% NBF was replaced
with 70% ethanol and stored at room temperature. Staining was performed on 4-micron thick
sections cut from formalin fixed paraffin embedded tissue. Slides were deparaffinized and
hydrated stepwise. Combination Periodic Acid-Schiff’s Stain staining was carried out on 4 µm
sections, along with appropriate positive controls per standard protocols (Luna, 1968; Sheehan
and Hrapchak, 1980). After staining, slides were scanned and analyzed and images were
prepared using the HALO image analysis software (PerkinElmer). The left hemisphere was
frozen in liquid nitrogen, pulverized using the Freezer/Mill Cryogenic Grinder, and the powdered
tissue was stored at -80°C. Aliquots of pulverized tissue were weighed and resuspended in
BioVision assay buffer for the ELISA, added directly to 30% KOH for polysaccharide
determination via the Pflüger method, or used for metabolite extraction.
GCMS metabolomics analysis
20 mg pulverized mouse brain were extracted for polar metabolites using 1ml of ice cold 50%
methanol. The polar fraction was transferred to a V-shaped GCMS glass vial and dried using a
SpeedVac (Thermo) followed by derivatization and GCMS analysis. Dried polar samples were
derivatized by sequential addition of 20 mg/ml methoxylamine hydrochloride in pyridine then
the trimethylsilylating agent N-methyl-N- trimethylsilyl-trifluoroacetamide (MSTFA) with brief
agitation in between at 37 oC. After cooling, the derivatized mixture analyzed by GCMS. GCMS
protocols were similar to those described previously (Jung and Oh, 2015; MacRae et al., 2012),
except a modified temperature gradient was used for GC: Initial temperature was 130° C, held
for 4 minutes, rising at 6° C/minutes to 243° C, rising at 60° C/minutes to 280° C, held for 2
minutes. The electron ionization (EI) energy was set to 70 eV. Scan (m/z:50-800) and full scan
mode were used for metabolomics analysis. Mass spectra were translated to relative metabolite
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abundance using the Automated Mass Spectral Deconvolution and Identification System
(AMDIS) software matched to the FiehnLib metabolomics library (available through Agilent) for
retention time and fragmentation pattern matching with a confidence score of >80 (Fiehn, 2016;
Fiehn et al., 2000; Kind et al., 2009). For mono-, di- and trisaccharide quantitation, molecular
ions 319 (mono) with a retention time between 17.5 and 18.5 min were used, 361 (di) with a
retention time between 24.5 and 26.5 min were used, and 361 (tri) with a retention time between
31 and 32 min were used. Values were first normalized to norvaline within the sample to account
for sample loss, then DNA-derived thymine to represent input volume.
QUANTIFICATION AND STATISTICAL ANALYSIS
For quantification of LB size and distribution, individual LBs in 3-5 micrographs were
measured manually using ImageJ and a frequency distribution was calculated for LBs from each
tissue type using Prism software (GraphPad) and a bin width of 1 μm. Only clearly delineated
LBs were measured; clumps and dust-like particles were excluded. Statistical significance of
polysaccharide reduction in cultured cells and animal tissues was determined using the Prism
software (GraphPad). A t-test was used when two groups were present, and two-way analysis of
variation (ANOVA) was used for comparing three groups or more. Data are represented as mean
± standard error of the mean (SE) or standard deviation (SD), as indicated. For in vivo
experiments, the numbers of animals (n) per group are indicated. PCA and clustering heatmap
analysis were performed using the ClustVis package for R (available through Github,
https://github.com/taunometsalu/ClustVis) (Metsalu and Vilo, 2015). All available metabolomics
data points were used for multivariate analysis.
SUPPLEMENTAL INFORMATION
Supplementary Figures. Figures S1-S11.
Table S1. List of all metabolites and their relative abundance per animal utilized in PCA and
heatmap analyses, related to Figure 7.
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Figures:

Fig. 1. The antibody-enzyme fusion VAL-0417 degrades starch, a proxy for LBs. (A)
Degradation of starch by a panel of amylases. 1 mg of starch was incubated with 5 µg of amylase
overnight with constant agitation, then soluble and insoluble fractions were separated by
centrifugation. Degradation product in the soluble fractions was quantified by measuring glucose
equivalents (i.e. glucan). Reactions were performed in triplicate and data shown are means ± SD.
(B) Schematic representation of VAL-0417. The gene encoding the human IgG1 Fab heavy
chain fragment (H) was fused to AMY2A, encoding human pancreatic α-amylase, and
coexpressed with the gene encoding the human light chain (L) in HEK293-6E cells. Heavy and
light chain signal peptides were included to facilitate proper folding and assembly of the Fab
fragment. The predicted molecular weight of each polypeptide is shown. (C) Purity of VAL0417 assessed by reducing (+BME) and nonreducing (-BME) SDS-PAGE. (D) Chemical
structure of the α-amylase-specific substrate E-G7-pNP. Reducing (inner) and non-reducing
(outer) ends of the substrate are displayed. (E) Degradation of 1 mg starch after a 2-hour
incubation with increasing amounts of VAL-0417, expressed as glucan released in the soluble
fraction. Mean ±SD of triplicate reactions are shown. (F) Scanning electron micrographs of
starch granules in the absence of treatment and after overnight treatment with VAL-0417.
Samples were visualized at 2kV by an FE Quanta 250 scanning electron microscope.
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Fig. 2. A novel protocol for isolating native LBs from LD mice. (A) LB purification scheme. (B)
Polysaccharide was purified at different steps in the protocol via the Pflüger method and
quantitated via glucose measurement following hydrolysis. Initial tissue weights and total
polysaccharide at each step are shown. (C) Polysaccharide yields normalized to tissue weight.
Triplicate samples were removed from each fraction and each measured in triplicate. Mean ±SD
are shown. (D) Phosphate content of LBs from skeletal muscle and normal rabbit muscle
glycogen. Mean ±SD of triplicate measurements are shown. (E) Normalized iodine spectra of
purified LBs compared to commercial liver glycogen and amylopectin. Spectra shown are an
average of 3 replicates. (F) Brain, (G) heart, and (H) skeletal muscle LBs stained with Lugol's
solution and visualized using a Zeiss Axioimager Z1.
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Fig. 3. Scanning electron micrographs of isolated LBs. Scanning electron micrographs of LBs
purified from brain (A), heart (B), and skeletal muscle (C) displayed using the same scale. LBs
from skeletal muscle are also shown at a higher magnification (D). Samples were visualized at 2
kV using an FE Quanta 250.
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Fig. 4. VAL-0417 degrades LBs in vitro. (A) Degradation of 50 µg LBs from different tissues
after overnight incubation with 0, 1, or 10 µg VAL-0417. (B) LBs from different tissues after
overnight incubation +/- 10 µg VAL-0417. Insoluble fractions were resuspended postdegradation, stained with Lugol's solution, and visualized using a Nikon Eclipse E600. (C)
Iodine absorbance in pellet fractions after incubation of WT and Epm2a-/- skeletal muscle
homogenates +/- 25 µg VAL-0417. In (A), (C), and (E) mean ± SD of triplicates are shown. (D)
HPAEC-PAD chromatogram of degradation product after incubation with VAL-0417 for 168
hours. Peak identities were determined based on the elution profile of degradation buffer and
glucan standards. The chromatogram is representative of triplicate experiments, and
glucose/maltose quantification from the replicates is shown in (E). (E) Quantification of glucose
and maltose at various time points throughout the degradation reaction of LBs with VAL-0417.
Product released are expressed as a percentage of total LBs.
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Fig. 5. VAL-0417 uptake and polysaccharide reduction in cell culture. (A) Rat1 cells and
HEK293 cells stably expressing PTG and PP1Cα after 20-hour treatment with increasing
concentrations of VAL-0417. VAL-0417 levels were assessed by Western blotting using an antiAMY2A antibody. ENT2 levels were also quantified by Western blotting. (B) Polysaccharide
levels per well in Rat1 and HEK293-PTG/PP1Cα cells after 20-hour treatment with VAL-0417.
Data shown are a mean of 4 measurements ± SE. Statistical significance determined by t-test is
indicated: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Fig. 6. VAL-0417 reduces LB load in vivo after intramuscular (IM) or intravenous (IV) injection.
(A) Biodistribution of VAL-0417 levels determined by sandwich ELISA after IM injection of
WT mice with PBS or 0.6 mg VAL-0417. (B) Quantification of polysaccharide in the injected
gastrocnemii of WT and Epm2a-/- mice after 3 IM injections of PBS or VAL-0417 administered
over the course of one week. (C) Quantification of polysaccharide in the heart of WT and
Epm2a-/- mice after 4 IV injections of PBS or VAL-0417 administered over a two-week period.
Polysaccharides in (B) and (C) were isolated via the Pflüger method and quantified by glucose
measurement assays following hydrolysis. (D, E) PAS-stained heart tissue of WT (D) and
Epm2a-/- (E) mice after IV treatment regimen. Intensely staining PAS-positive deposits are LBs
(purple). Tissues were counterstained with hemotoxylin (blue).
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Fig. 7. VAL-0417 reduces LB load and reverses metabolic derangement in vivo after continuous
ICV infusion. (A) Representative photograph of six 2.0 mm coronal sections. Evans blue dye
was injected through the cannula into the lateral ventricle to verify its location within slice 2. (B)
Polysaccharide content normalized to protein content in Epm2a-/- brain slices after 28 days of
continuous ICV infusion of VAL-0417 or PBS. (C) Total brain polysaccharide normalized to
tissue weight from untreated, PBS treated, and VAL-0417 treated Epm2a-/- mice after 8-day
ICV infusion. (D) VAL-0417 levels in PBS and VAL-0417 treated animals determined by
ELISA. In (B), (C), and (D) at least three technical replicates were performed for each isolated
slice to determine an average per slice per animal, and data shown are the mean from each
treatment group ± SE. The numbers of animals in each treatment group (n) are shown. Statistical
significance is indicated as determined by ANOVA (B) and t-test (C): * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001. (E) PAS-stained brain slices of PBS and VAL-0417 treated Epm2a-/- mice after
8-day ICV infusion. LB deposits appear purple; tissue was counterstained with hemotoxylin
(blue). (F) Two-dimensional principle component (PC) plots for polar metabolites of PBS and
VAL-0417 treated Epma2-/- animals (orange and blue dots, respectively) after 8-day infusion
compared to untreated WT and Epm2a-/- controls (black and red dots, respectively). There is a
clear separation between the groups, which has been shaded accordingly. (G) Relative abundance
of mono-, di- and tri-saccharides determined by GCMS from untreated WT and Epm2a-/- mice
36

and also Epm2a-/- mice treated with PBS or VAL-0417. Statistical significance was determined
by two-way ANOVA: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
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Supplementary Material
Materials and Methods
Expression and purification of VAL-0417
The cDNA encoding the human IgG1 Fab-linker-AMY2A heavy chain and light chain were
synthetically produced with codon optimization for mammalian cell expression and cloned into
pTT5. HEK293 cells expressing a truncated variant of the Epstein Barr Virus nuclear antigen 1
(HEK293-6E) increase the volumetric yield of monoclonal antibodies and fragments and were
used for VAL-0417 expression (Jager et al., 2013). 2 1L cultures of HEK293-6E cells in 2L
shake flasks were transfected with 1 mg of total plasmid DNA/L (1:1 ratio heavy chain:light
chain) culture using PolyPlus linear Q-PEI at a 1:1.5 (w/v) DNA:PEI ratio. Culture parameters
were monitored using a ViCell XR (Beckman Coulter) for density and viability. Culture was
harvested 5 days post transfection via centrifugation for 5 minutes at 1000×g. The conditioned
culture supernatant was clarified by centrifugation for 30 minutes at 9300×g.
Pre-packed CaptureSelect IgG-CH1 affinity columns (Fisher) were equilibrated in PBS (pH
7.2). VAL-0417 from 2 L of exhausted supernatant was top-loaded onto affinity columns (2 x 1
mL columns in tandem) at 4°C overnight. The column was washed with approximately 15
column volumes (CV) of PBS, 15 CV of buffer B (1×PBS with 500 mM NaCl, pH 7.2) and 15
CV of PBS. The resin-bound fusion protein was eluted with 10 CV of Buffer C (30 mM NaOAc,
pH 3.5-3.6), collecting the protein in 1 mL fractions diluted in 1/10th volume Buffer D (3 M
NaAcetate pH~9.0) to neutralize. To minimize the elution volume, elution was paused for
several minutes between each fraction collected. Fractions were analyzed by A280 prior to
pooling fractions and pools were analyzed by SDS-PAGE. VAL-0417 remained in the nonbound pool from the first affinity chromatography pass. The above procedure was repeated to
capture remaining fusion protein. The affinity pools were combined prior to dialysis. The
combined CaptureSelect IgG-CH1 affinity pool (18 mL) was dialyzed against 3 x 1 L of dialysis
buffer (20 mM Histidine, 150 mM NaCl, pH 6.5) at 4°C. The dialyzed pool was concentrated to
1 mg/mL using a VivaSpin 20 (10K MWCO, PES membrane) centrifugal device prior to final
analysis and storage at -80°C. Purified Fab-AMY was analyzed by size exclusion
chromatography (Agilent HP1100) showing a single peak before and after a freeze-thaw cycle,
indicative of a single, stable species.
Pflüger method for polysaccharide isolation
Glycogen and polyglucosan from Epm2a-/- and Epm2b-/- mice have been purified and
characterized by multiple groups using the Pflüger method, but a chaotropic salt must be added
to enhance the efficiency of polyglucosan precipitation (Tagliabracci et al., 2008). We wanted to
clarify that under native conditions, and prior to the Pflüger treatment, LBs in Epm2a-/- and
Epm2b-/- tissues are intact, micron-sized structures (Fig. 2 F to H, Fig. 3, and fig. S5B). Pflüger
treatment converts the LBs to much smaller polysaccharide molecules that are on the same
nanometer scale as glycogen molecules, but they contain elevated phosphate and an altered chain
length distribution (Nitschke et al., 2013; Tagliabracci et al., 2008). Thus, the term "LB" refers to
the native, micron-sized polysaccharide-containing structures found in LD tissues, and
"polyglucosan" refers to the abnormal polysaccharide comprising LBs, which is released with
Pflüger treatment.
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The Pflüger method is direct and very sensitive and was used to track polysaccharide yield
throughout the native LB purifications or to detect polysaccharide content of mouse tissues for in
vivo studies. Aliquots from native LB purifications or tissue homogenates were added to 10 vol.
30% KOH, boiled for 2 hours, and allowed to cool. 2 vol. cold ethanol and 10 µL LiCl (1 M or
20 mM) were added, and samples were precipitated overnight at -20°C. Precipitated samples
were centrifuged for 10 min at 16,000×g at 4°C, the supernatant was removed, and the
polysaccharide pellet was resuspended in water. Two additional precipitations with cold ethanol
and LiCl were carried out, each for 1-2 hours at -20°C. The final pellet was washed in cold
ethanol and resuspended with vortexing in 200 µL water. Polysaccharide was quantified by
overnight hydrolysis with amyloglucosidase from Aspergillus niger (Sigma) and glucose
determination was carried out using the R Biopharm Inc. D-glucose kit (Fisher). Fluorescence
(ex340/em445) rather than absorbance of the NADPH product (stoichiometric to glucose) was
measured for higher sensitivity.
Separation of glycogen and LBs in native LB purification
After the initial centrifugation step in the LB purification, a fraction of the heart and muscle
glycogen was consistently present in the supernatant (Fig. 2, B and C). In our preliminary
purifications, we found that the homogenate and pellet fractions stained brown with Lugol's
iodine after boiling, as did the final LBs and amylopectin, but the supernatants stained yellow
like glycogen (fig. S2A). We also stained the Pflüger-purified polysaccharide fractions from our
large-scale preparations in Figure 2C with Lugol's iodine, measured absorbance at 550 nm, and
compared the values to the polysaccharide concentrations determined by hydrolysis and glucose
measurement (fig. S2B). While the polysaccharide from the supernatant did not absorb at 550
nm, polysaccharide from the pellet, filtrate and final fractions produced a high absorbance
relative to concentration. Polysaccharide in the homogenate fraction was less absorbent relative
to concentration. These data indicate that the polysaccharide in the heart and muscle tissue
homogenates included both glycogen and polyglucosan (in the form of LBs), that were separated
into supernatant and pellet fractions after low-speed centrifugation. No polysaccharide was
detected in the supernatant fractions from brain (Fig. 2, B and C). This result is consistent with
the observation that in normal mice, glycogen levels are lower in brain than in other tissues in
part due to its rapid catabolism after euthanasia (Oe et al., 2016).
Iodine-based measurements
Lugol's iodine was prepared as a 20×stock (1.5 M KI and 100 mM I2). To detect LBs in
preliminary purifications, 50 µL samples from purification fractions were boiled for 15 minutes
on a 95°C heat block, clarified by centrifugation (16,000×g for 1 min), and 35 µL of the
supernatant was added to 50 µL 1×Lugol's iodine and 15 µL water for 100 µL total (fig. S2A).
To analyze iodine absorbance of polysaccharide from LB purifications, Pflüger-isolated
polyglucosan fractions were added to 50 µL 1×Lugol's iodine for 100 µL total and absorbance
was measured at 550 nm. Absorbance was graphed alongside glucose-based concentrations to
illustrate the fractionation of polyglucosan and glycogen into supernatant and pellet fractions,
respectively (fig. S2B). For spectral scans, 50 µg LBs, rabbit liver glycogen (Sigma), and potato
amylopectin (Sigma) were solubilized by boiling for 30 min and added to 50 µL 1×Lugol's
iodine for 100 µL total. Absorbance scans were performed at 400-800 nm in 10 nm steps.
Determination of LB phosphate content
39

Muscle glycogen and LBs contain covalent phosphate linked to the C2, C3, and C6 hydroxyls of
glucose moieties, and the relative ratios of these modifications are equivalent (DePaoli-Roach et
al., 2014; Nitschke et al., 2013; Tagliabracci et al., 2011). Boiling in mild HCl hydrolyzes
glycosidic bonds and releases the acid-labile C2- and C3-linked phosphate leaving C6
phosphoesters intact in the form of glucose-6-phosphate (Nitschke et al., 2013). Thus, inorganic
phosphate after mild acid hydrolysis represents only C2- and C3-linked phosphate, i.e. two-thirds
of total phosphate. To determine phosphate content, skeletal muscle LBs were boiled for 2 hours
at 95°C in 1 M HCl. Reactions were neutralized with NaOH and inorganic phosphate in the
sample was determined using the Pi ColorLock Gold Phosphate Detection System (Innova
Biosciences). Glycogen purified from rabbit skeletal muscle as previously described was used as
a positive control, and the levels of phosphate detected using our method are consistent with twothirds of published total phosphate levels (DePaoli-Roach et al., 2014).
Generation of HEK293-PTG/PP1Cα cells and polysaccharide quantitation
Protein Phosphatase 1 (PP1) stimulates glycogen synthesis by both dephosphorylating and
activating glycogen synthase and inhibiting glycogen phosphorylase, the primary enzymes
catalyzing glycogen synthesis and degradation, respectively (Newgard et al., 2000). Protein
targeting to glycogen (PTG) is a regulatory, glycogen-targeting subunit of PP1 that stimulates
glycogen synthesis when overexpressed in cell lines (Printen et al., 1997; Worby et al., 2008).
Constitutive overexpression of PTG in WT mice has been shown to lead to cerebral
polyglucosan accumulation in Epm2b-/- mice (Duran et al., 2014). We sought to design a cell
line that accumulates polyglucosan like that which makes up LBs.
HEK293 cells (Graham et al., 1977) were co-transfected with plasmids pCDH-FLAG-PTG
and pCDH-(HA)3-PP1Cα-GFP harboring mouse PTG and the human PP1Cα (catalytic alphasubunit of PP1) cDNAs, respectively. Mixed clones were selected for ~10 days in the presence
of 1 µg/ml hygromycin and 0.2 mg/ml puromycin, expanded and stored in liquid N2. Analyses of
protein expression and glycogen synthase activity ratio in the absence and presence of glucose-6phosphate indicated that both proteins were expressed, and the glycogen synthase activity ratio
was increased 3-fold, from 0.02 in control cells to 0.06 in transfected cells. Quantitation of the
expression of PTG and PP1Cα is difficult because the basal levels are very low, undetectable
under our conditions.
For quantitation of polysaccharide levels HEK293, HEK293-PTG/PP1Cα and
Rat1fibroblasts were plated in 96-well plates at a density of 40,000 cells/well. After 48 hr, media
was changed and the next day, the cells were washed 3 times with PBS followed by overnight
incubation at 40°C in 50 µL of 0.2 M sodium acetate pH 4.8 containing 0.2% Triton and 0.3
mg/ml amyloglucosidase (Aspergillus niger; Sigma). Identical cell cultures were lysed in 50 µL
of in 0.2 M sodium acetate pH 4.8 containing 0.2% Triton for protein determination by the
Bradford procedure.
After overnight digestion, polysaccharide was measured by transferring 40 µL samples to a
new 96-well plate. A 160 µL reaction mixture consisting of 0.375 M ethanolamine pH7.6, 5 mM
MgCl2, 1.12 mM NADP, 2.5 mM ATP and 0.2 Units of G6PDH (Roche Biochemicals
10127655001) was added and OD340 nm was recorded. Subsequently, 0.75 units of hexokinase
(Roche 11426362001) were added, the reaction incubated at room temperature for 30 min and
OD340 recorded again. Background absorbance was subtracted from sample absorbance and
glucose equivalents were determined based a digested glycogen standard curve. The engineered
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HEK293 line accumulated >30-fold more polysaccharide than the native HEK293 cells, and
twice the level of normal glycogen found in Rat1 cells (fig. S6).
Enzyme-linked immunosorbent assay (ELISA)
The capture antibody raised against the 3E10 Fab fragment was generated by Valerion
Therapeutics (Concord, MA). Wells of a 96-well plate were incubated with 100 µL of capture
antibody overnight (~16 hours) at a final concentration of 2 µg/ml in PBS. All incubations were
done in a humidified chamber. Wells were then rinsed 3 times with 200 µL PBS followed by
incubation for 1 hour with 200 µL of blocking solution (5% non-fat milk in PBS). Wells were
then rinsed 3 times with 200 µL PBS. 100 µL of diluted tissue homogenates were added and
incubated for 1 hour. Wells were then rinsed 3 times with 200 µL of Tris-buffered saline (TBS)
and 100 µL of primary antibody (anti-AMY2A, Abcam #ab21156) in 5% non-fat milk and TBS
was added and incubated for 1 hour. The wells were then washed (solution added and incubated
for 5 minutes before being removed) 3 times with TBS. 100 µL of secondary antibody (antirabbit IgG, HRP-linked, Cell Signaling Technology 7074) in 5% non-fat milk in TBS was added
and incubated for 1 hour. Wells were then washed 5 times with TBS. 100 µL of TMB substrate
(ThermoFisher N301) was added and a timer started. After the highest concentration of standard
curve saturated or a pre-set time was met, the reaction was stopped by adding 100 µL of stopping
solution (0.18% H2SO4). The plate was then read for absorbance at 450 nm.
Supplementary Figures

Fig. S1. Starch degradation with different VAL-0417:starch ratios. (A) Degradation with low
ratio (10 µg VAL-0417, 1 mg starch). (B) Degradation with high ratio (10 µg VAL-0417, 100 µg
starch).
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Fig. S2. Iodine staining of LB purification fractions. (A) 50 µL samples were removed from
homogenate, supernatant, and pellet fractions during preliminary LB purifications from skeletal
muscle, boiled for 30 minutes, and clarified by centrifugation. 30 µL of the clarified sample was
diluted with 15 µL water and stained with 50 µL 1x Lugol's solution in a microplate. Commercial
liver glycogen and amylopectin were also stained as controls. (B) Concentration vs. iodine
absorbance at 550 nm of Pflüger-isolated polysaccharide from skeletal muscle at each step of the
purification scheme.

Fig. S3. Size distribution of LBs purified from different tissues and appearance of dust-like
particles. Frequency distribution of LBs from each tissue type: (A) brain (total count: 473), (B)
heart (total count: 247), and (C) skeletal muscle (total count: 252). Two fields of view from (D)
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brain and heart (E) LB preparations containing numerous dust-like particles are shown. Black
boxes indicate areas that have been magnified and are labeled correspondingly (e1, e2, etc.).
Occasionally very large bodies were observed (10-20 µm). They were difficult to distinguish
from tightly packed clumps, so they were excluded from the size distribution histograms.

Fig. S4. Scanning electron micrographs of LBs from brain, heart and skeletal muscle, washed in
ethanol, dried, and applied to carbon tape. Samples were visualized at 2kV under high vacuum
by an FE Quanta 250.

Fig. S5. Soluble fractions of untreated and treated brain LBs (BrLBs) after degradation reactions.
Samples from the soluble fractions and total reactions were stained with Lugol's solution and
visualized using a Zeiss Axioimager Z1.
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Fig. S6. Purification of LBs from skeletal muscle of 12-month-old Epm2b-/- mice. (A) LB
purification yields. Mean ± SD of triplicate measurements are shown. (B) Epm2b-/- LBs stained
with Lugol's solution and visualized by light microscopy. (C) Comparison of size distribution of
skeletal muscle LBs from Epm2a-/- and Epm2b-/- mice. (D) Normalized iodine spectra of
Epm2b-/- and Epm2a-/- skeletal muscle LBs. The spectral data are an average of 3 replicates.

Fig. S7. HPAEC-PAD chromatograms of control samples and additional time points from LB
degradation with VAL-0417. (A) Overlay of control chromatograms: degradation buffer only
(black line), LBs only (red line), and a mixture of 1 µg glucose and 1 µg maltose standards for
quantitation (blue line). A small amount of maltose and low molecular weight oligosaccharides
were detected in the LB control. Additional time points from the 168 hour LB degradation
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experiment with VAL-0417: (B) 24 hours, (C) 48 hours, and (D) 72 hours. Each chromatogram
is representative of triplicate chromatograms. Small shifts in retention time (≤1 min) are typical
between HPAEC-PAD runs. (E) Maltrin100, a mixture of low molecular weight
oligosaccharides, was used as a standard for verifying degrees of polymerization (DP), i.e.
number of glucose units.

Fig. S8. Polysaccharide levels relative to protein concentration in three cell lines: Rat1, HEK293,
and HEK293 stably expressing PTG and PP1Cα. Data are expressed as the mean of 12 replicates
± SE.

Fig. S9. Comparison of intrathecal (IT) versus intracerebroventricular (ICV) routes of
administration in WT mice. (A) Distribution of VAL-0417 levels using the sandwich ELISA in
PBS- and VAL-0417-treated WT brain slices after intrathecal (IT) or intracerebroventricular
(ICV) infusion. (B) Distribution of VAL-0417 activity in the same slices measured using the
BioVision amylase activity assay. Data shown are a mean of 3 measurements ± SE.
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Fig. S10. Regional distribution of LB load in PBS and VAL-0417 treated Epm2a-/- (KO)
animals compared to untreated WT and Epm2a-/- controls. PAS-stained slides were
counterstained with hematoxylin (blue). LBs appear as PAS+ inclusions (bright purple). Slides
were scanned and images were prepared using the HALO software (PerkinElmer). The left
column represents the entire slice at low magnification; the other columns show individual
regions at higher magnification and are labeled accordingly. Brain slices are representative of all
animals analyzed for each group.
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Fig. S11. Clustering heat map analysis illustrating the similarities in metabolite profiles between
untreated WT and Epm2a-/- mice treated with VAL-0417 compared to PBS treated Epm2a-/(KO) mice. Each row represents a metabolite, while each column represents an individual
mouse. Colors indicate the magnitude of the difference between groups (log2 transformed
relative abundance). The PBS-treated Epm2a-/- group was omitted to prevent confounding the
groups.
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